

CTAD Alzheimer's 2023

Clinical Trials on Alzheimer's Disease

©Mircea Costina

Preliminary program



+



In-Person

Remote

October 24-27, 2023

Boston, MA - USA

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14 / Barcelona '15 / San Diego '16
Boston '17 / Barcelona '18 / San Diego '19 / Virtual '20 / Boston '21 / San Francisco '22

www.ctad-alzheimer.com

Email: ctad@ant-congres.com

JPAD
The Journal of Prevention of Alzheimer's Disease

SUMMARY

Editorial	3
Organizing & Scientific Committees	4
Lifetime Achievement Award	5
Keynotes	6
Onsite Program	7
Tuesday, October 24	10
Wednesday, October 25	11
Thursday, October 26	14
Friday, October 27	16
Poster presentations	20
Congress Venue	39

CTAD
2022

Clinical Trials on Alzheimer's Disease

TOWER 2
Ballroom Level

Editorial

CTAD 2023: What is coming next in Alzheimer's Disease clinical research?

The 16th Clinical Trials on Alzheimer's Disease conference (CTAD), will be held in Boston, Massachusetts (USA) on **October 24-27, 2023**.

Last November, in San Francisco, California, CTAD 2022 attracted over 2,800 international leaders to discuss the future of Alzheimer's disease clinical research with pivotal readouts from major pharmaceutical companies and new avenues of treatment beyond Amyloid and Tau.

This year has already seen more breakthrough advances in anti-amyloid treatments, the emergence of diagnostic blood-based biomarkers and encouraging results from other Phase 1 to Phase 3 AD clinical trials.

At CTAD 2023, the scientific program will again focus on bringing cutting edge clinical research, thought-provoking roundtable and symposia on the latest advances in AD clinical research. CTAD 2023 brings together leaders from academic research centers, patient advocacy groups, international research coalitions and pharmaceutical companies.

CTAD is also committed to exploring new avenues beyond amyloid-clearing immunotherapy including combination trials of disease-modifying agents, gene therapy, vaccines and multimodal interventions.

The CTAD scientific program is based on a strict peer-review abstract selection process. CTAD 2023 is a great opportunity for clinical and research teams around the world to showcase their work in AD clinical trials.

Boston has long been a hub of laboratory, translational and clinical neuroscience research, and is thrilled to host CTAD this year.

We look forward to welcoming you to CTAD 2023 in Boston this Fall!



Reisa Sperling, MD
President of the CTAD23 Scientific Committee



President of the CTAD23 Scientific Committee

Reisa Sperling, MD

Harvard Medical School

and Brigham and Women's Hospital, Boston, MA

Organizing and Scientific Committees

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN* (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Randall J. BATEMAN (St. Louis, USA); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Steven DEKOSKY (Miami, USA); Michael C DONOHUE (San Diego, USA); Rachele DOODY (Basel, Switzerland); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Howard FILLIT (New-York, USA); Nick FOX (London, UK); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Nutley, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); Lefkos T.MIDDLETON* (London, UK); José Luis MOLINUEVO (Barcelona, Spain); Ronald PETERSEN (Minnesota, USA); Michael S.RAFII (San Diego, USA); Rema RAMAN (San Diego, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Las Vegas, USA); Stephen SALLOWAY (Providence, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Yong SHEN (Heife, China); Jiong SHI (Las Vegas, USA); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Jacques TOUCHON* (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS* (Toulouse, France); Michael W. WEINER* (San Francisco, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

*Organizing Committee Member

CTAD 2023

Lifetime Achievement Award

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Randall J. Bateman, MD in recognition for his pioneering work in Alzheimer's Disease Research and Plasma Biomarkers in AD diagnostics.



Randall J. Bateman, MD

Charles F. and Joanne Knight Distinguished Professor of Neurology, Director of the Tracy Family SILQ Center and Bateman Lab for Neurodegenerative Biology, the Dominantly Inherited Alzheimer Network (DIAN), and the Knight Family DIAN Trials Unit (DIAN-TU), Washington University in St. Louis, St. Louis, MO (United States)

Dr. Bateman's research focuses on the pathophysiology and development of improved diagnostics and treatments of Alzheimer's disease. Dr. Bateman's lab accomplishments include pioneering Stable Isotope Labeling Kinetics (SILK), furthering insights of human circadian patterns, and human in vivo control of the processing of amyloid-beta, apolipoprotein E, tau, and neurofilaments. His lab reported a highly accurate amyloid-beta blood test for Alzheimer's disease amyloid plaques and also identified specific tau species in blood for accurate quantitation of amyloid pathology, has described the biology and pathophysiology of tau species in brain, CSF and blood, discovered unique soluble tau species that correlate with tau pathology, and also discovered that tau production is increased in Alzheimer's disease. Dr. Bateman has received awards including the Beeson Award for Aging Research, Alzheimer's Association Zenith Award, Scientific American top innovator, the Glenn Award for Aging Research, the MetLife Foundation Award for Medical Research, the Potamkin Prize, and is a member of the National Academy of Inventors and the National Academy of Medicine.

Keynotes



“Clinical Trials in Alzheimer’s Disease Prevention”

Sandrine Andrieu, MD, PhD

Professor of Public Health, Clinical Epidemiology and Public Health Department, Toulouse University Hospital, Toulouse (France)

Dr. Sandrine Andrieu is professor of public health of the clinical epidemiology and public health department at the Toulouse University Hospital (France) and adjunct professor at the University of New Mexico (United States). Since 2009 she has been in charge of the Aging Research team at the Center for Epidemiology and Research in Population Health. She served as the Director of the Research Center for Epidemiology and Research in Population Health (UMR1295 INSERM - University Paul Sabatier) from 2011 to 2020. She has published more than 250 international papers and book chapters in the field of aging. She is involved in large prevention studies in neurodegenerative diseases (GuidAge, MAPT) and in European projects (HATICE study, MIND-AD, PRODEMOS). Her main topic of research is Alzheimer’s Disease and prevention of age-related loss of functions and healthy aging. She is the past president of the French National Society of Geriatrics and Gerontology.



“Pathophysiology insights of blood tests, disease modifying treatments, and the potential for prevention of Alzheimer’s disease”

Randall J. Bateman, MD

Charles F. and Joanne Knight Distinguished Professor of Neurology, Director of the Tracy Family SILK Center and Bateman Lab for Neurodegenerative Biology, the Dominantly Inherited Alzheimer Network (DIAN), and the Knight Family DIAN Trials Unit (DIAN-TU), Washington University in St. Louis, St. Louis, MO (United States)

Dr. Bateman’s research focuses on the pathophysiology and development of improved diagnostics and treatments of Alzheimer’s disease. Dr. Bateman’s lab accomplishments include pioneering Stable Isotope Labeling Kinetics (SILK), furthering insights of human circadian patterns, and human in vivo control of the processing of amyloid-beta, apolipoprotein E, tau, and neurofilaments. His lab reported a highly accurate amyloid-beta blood test for Alzheimer’s disease amyloid plaques and also identified specific tau species in blood for accurate quantitation of amyloid pathology, has described the biology and pathophysiology of tau species in brain, CSF and blood, discovered unique soluble tau species that correlate with tau pathology, and also discovered that tau production is increased in Alzheimer’s disease. Dr. Bateman has received awards including the Beeson Award for Aging Research, Alzheimer’s Association Zenith Award, Scientific American top innovator, the Glenn Award for Aging Research, the MetLife Foundation Award for Medical Research, the Potamkin Prize, and is a member of the National Academy of Inventors and the National Academy of Medicine.



“What we have learned about ARIA in anti-amyloid antibody treatment in mice and the implications for AD clinical trials”

Cynthia A. Lemere, PhD

Associate Professor of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (United States)

Dr. Lemere is a Scientist in the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital (BWH) and an Associate Professor of Neurology at Harvard Medical School in Boston, MA USA. Her research focuses on understanding and using the immune system therapeutically to prevent and treat Alzheimer's disease. Dr. Lemere earned a bachelor's degree in psychology and education from Mount Holyoke College and a master's in neurobiology from SUNY Albany. Dr. Lemere examined Alzheimer's-related brain changes in people with Down syndrome in the Selkoe Laboratory at BWH while pursuing her doctorate in pathology at Boston University School of Medicine. Her current research involves: 1. Non-clinical studies of antibody treatments targeting a pathogenic form of amyloid-beta protein found in plaques in Alzheimer's disease brain; 2. The role of the innate immune system's complement signaling in aging and Alzheimer's disease; and 3. The effects of deep space galactic cosmic radiation on brain aging and the risk of Alzheimer's disease in studies in mouse models and human neural cells in preparation for NASA's upcoming missions to the moon and Mars. Her lab is funded by NIH and NASA. Dr. Lemere serves as an advisor to the Alzheimer's Association, the BrightFocus Foundation, the Cure Alzheimer's Fund, and the AD/PD International Meeting. In addition, she serves as a consultant for several companies.



“Alzheimer's Disease: the Drug Development Pipeline and Emerging Therapies”

Jeffrey Cummings, MD, ScD

Joy Chambers-Grundt Professor of Brain Science, Director of the Chambers-Gundt Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, NV (United States)

Dr. Cummings is globally known for his contributions to Alzheimer's research, drug development, and clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer's disease through many awards including the Ronald and Nancy Reagan Research Award of the national Alzheimer's Association (2008), Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017), Distinguished Scientist Award of the American Association of Geriatric Psychiatry (2010), Bengt Winblad Lifetime Achievement Award from the national Alzheimer's Association (2019), and the Alzheimer's Drug Discovery Foundation's Melvin R. Goodes Prize. He was featured in the Gentleman's Quarterly (June 2009) as a “Rock Star of Science™.” Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London. Dr. Cummings was formerly Director of the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. Dr. Cummings' interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. He has authored or edited 43 books and published over 800 peer-reviewed papers.

Keynotes



“Creating more Equitable and Valid Alzheimer’s Clinical Trials for the 21st Century”

Monica Rivera-Mindt, PhD

Professor of Psychology, Latinx Studies, and African & African American Studies, Fordham University and joint appointment in Neurology, Icahn School of Medicine at Mount Sinai, New York, NY (United States)

Dr. Mónica Rivera Mindt, a board-certified neuropsychologist, is Past-President of the Hispanic Neuropsychological Society and a tenured Professor of Psychology, Latinx Studies, and African & African American Studies at Fordham University with a joint appointment in Neurology at the Icahn School of Medicine at Mount Sinai. Her multidisciplinary, community-based research is funded by the NIH/National Institute of Aging (NIA), the Alzheimer’s Association, NSF, and Genentech. Her work primarily focuses on the intersection between cultural neuroscience and health inequities in cognitive aging. Her current studies are examining genetic, cerebrovascular, and sociocultural risk factors for cognitive impairment and dementia in ethnoculturally diverse populations, as well as ways to increase diverse representation in cognitive aging and dementia research. She has authored more than 100+ peer-reviewed publications and book chapters. In addition, she is Co-Lead of the NIA-funded Alzheimer’s Disease Neuroimaging Initiative’s (ADNI) Engagement Core. At the national level, Dr. Rivera Mindt recently served as Chair of NIH/NIA’s AGCD-4 Study Section, and is a member of the CDC’s BOLD Public Health Center of Excellence on Dementia Risk Reduction Expert Panel, and the CDC/National Alzheimer’s Project Act’s (NAPA) Physical Activity, Tobacco Use, and Alcohol Workgroup. Locally, she serves as a Board Member for the Alzheimer’s Association’s NYC Chapter and a Treasurer for the Harlem Community & Academic Partnership (HCAP). As a bilingual (Spanish/English), Afro-Latinx/Indigenous neuroscientist, she brings a unique perspective to her research and is the recipient of several awards for her research, teaching, and contributions to the field, including the 2020 Martha Bernal Award for the Advancement of Diversity Training and Education in Clinical Psychology from the Council of University Directors of Clinical Psychology (CUDCP) and 2019 Hispanic Health Leadership Award from the National Hispanic Medical Association. She is also a Fellow of the American Psychological Association (Division 40, Society for Clinical Neuropsychology), the National Academy of Neuropsychology, and Hispanic Neuropsychological Society.



ONSITE PROGRAM

in Boston

Available via livestream
on the CTAD23
digital platform

Program at a glance

● Tuesday, OCTOBER 24

- 4.00 p.m. Welcome ceremony and CTAD Lifetime Achievement Award
- 4.30 p.m. **KEYNOTE 1:** Pathophysiology insights of blood tests, disease modifying treatments, and the potential for prevention of Alzheimer's disease
- 4.55 p.m. **SYMPOSIUM 1:** The Effects of Race and Gender on Amyloid Positivity
- 5.35 p.m. LATE BREAKING COMMUNICATIONS
- 6.45 p.m. CTAD Welcome Reception

● Wednesday, OCTOBER 25

- 8.00 a.m. POSTER WALKING TOUR
- 9.00 a.m. **KEYNOTE 2:** Creating more Equitable and Valid Alzheimer's Clinical Trials for the 21st Century
- 9.25 a.m. **SYMPOSIUM 2:** Donanemab in Early Symptomatic Alzheimer's Disease: Additional Insights from TRAILBLAZER-ALZ 2
- 10.05 a.m. Coffee break and poster session
- 10.35 a.m. LATE BREAKING ROUNDTABLE
- 11.05 a.m. ORAL COMMUNICATIONS
- 12.20 p.m. Lunch and poster sessions
- 1.20 p.m. LATE BREAKING SYMPOSIUM
- 2.00 p.m. ORAL COMMUNICATIONS
- 3.00 p.m. LATE BREAKING COMMUNICATIONS
- 3.45 p.m. Coffee break and poster session
- 4.15 p.m. **KEYNOTE 3:** Alzheimer's Disease: The Drug Development Pipeline and Emerging Therapies
- 4.40 p.m. LATE BREAKING COMMUNICATIONS

● Thursday, OCTOBER 26

- 8.00 a.m. POSTER WALKING TOUR
- 9.00 a.m. **Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease**
- 10.00 a.m. LATE BREAKING COMMUNICATIONS
- 10.30 a.m. Coffee break and poster session
- 11.00 a.m. **KEYNOTE 4:** Clinical Trials in Alzheimer's Disease Prevention
- 11.25 a.m. **SYMPOSIUM 3:** What can we LEARN from the A4 Study? Associations among longitudinal cognitive, functional, biomarker and imaging outcomes
- 12.05 p.m. Lunch and poster session
- 1.00 p.m. **ROUNDTABLE 2:** Forging the Path Forward: Capitalizing on Recent Alzheimer's Momentum through Strategic Investments in Novel Therapeutics
- 2.00 p.m. ORAL COMMUNICATIONS
- 3.15 p.m. **ROUNDTABLE 3:** What is meaningful enough for CMS to cover? – What is reasonable and necessary?
- 3.45 p.m. Coffee break and poster session
- 4.15 p.m. ORAL COMMUNICATIONS

● Friday, OCTOBER 27

- 8.00 a.m. POSTER WALKING TOUR
- 9.00 a.m. **KEYNOTE 5:** What we have learned about ARIA in anti-amyloid antibody treatment in mice and the implications for AD clinical trials
- 9.25 a.m. LATE BREAKING COMMUNICATIONS
- 10.00 a.m. Coffee break and poster session
- 10.30 a.m. ORAL COMMUNICATIONS
- 12.15 p.m. Lunch and poster sessions
- 1.15 p.m. LATE BREAKING COMMUNICATIONS
- 3.15 p.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Phase 1 Clinical Trials

● Tuesday,
OCTOBER 24



- 4.00 p.m **Welcome ceremony and CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research**
Presented to Randall J. Bateman, MD in recognition for his pioneering work in Alzheimer's Disease Research and Plasma Biomarkers in AD diagnostics
Introduction by Reisa Sperling, President of the CTAD23 Scientific Committee and the CTAD Organizing Committee
- 4.30 p.m **KEYNOTE 1**
Pathophysiology insights of blood tests, disease modifying treatments, and the potential for prevention of Alzheimer's disease
Randall J. Bateman, Washington University School of Medicine, St. Louis, MO (United States)
- 4.55 p.m **SYMPOSIUM 1**
The Effects of Race and Gender on Amyloid Positivity
Chair: Suzanne Schindler, Washington University St. Louis, St. Louis, MO (United States)
- Introduction : Determining amyloid status in different racial, ethnic, and gender groups
Suzanne Schindler, Washington University St. Louis, St. Louis, MO (United States)
- Presentation 1: Amyloid PET results from the GAP Bio-Hermes study: initial findings on differences between racial and ethnic groups
*Robin Wolz*¹, *Lynne Hughes*², *Richard Manber*¹, *Richard Mohs*², *John Dwyer*², *Douglas Beauregard*²
¹IXICO - London (United Kingdom), ²Global Alzheimer's Foundation - Washington (United States)
- Presentation 2: Race and Sex Effects on Rates of Amyloid Positivity in Real-World Memory Care: Insights from IDEAS and New IDEAS
*Charles Windon*¹, *Maria Carillo*², *Peggye Dilworth-Anderson*³, *Constantine Gatsonis*⁴, *Emily Glavin*⁵, *Lucy Hanna*⁶, *Bruce Hillner*⁷, *Andrew March*⁵, *Sid O'bryant*⁸, *Robert Rissman*⁹, *Barry Siegel*¹⁰, *Karen Smith*¹, *Christopher Weber*², *Consuelo Wilkins*¹¹, *Gil Rabinovici*¹
¹Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco - San Francisco (United States),
²Alzheimer's Association - Chicago (United States), ³Gillings School of Global Public Health, University of North Carolina-Chapel Hill - Chapel Hill (United States), ⁴Department of Epidemiology and Biostatistics, Brown University School of Public Health - Providence (United States), ⁵American College of Radiology - Reston (United States), ⁶Center for Statistical Sciences, Brown University School of Public Health - Providence (United States), ⁷Department of Medicine, Virginia Commonwealth University - Richmond (United States), ⁸Institute for Translational Research, University of North Texas Health Science Center at Fort Worth - Fort Worth (United States), ⁹Department of Physiology and Neuroscience, Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California - San Diego (United States), ¹⁰Mallinckrodt Institute of Radiology, Washington University in St Louis - St. Louis (United States), ¹¹Department of Medicine, Division of Geriatric Medicine, Vanderbilt University Medical Center - Nashville (United States)
- Questions and Answers
- 5.35 p.m **Late breaking communications**
- 6.45 - 7.45 p.m **CTAD Welcome Reception with the Support of the Alzheimer's Association** 

● Wednesday, OCTOBER 25

- 8.00 a.m. **POSTER WALKING TOUR** - Poster Hall
- 9.00 a.m. **KEYNOTE 2**
Creating more Equitable and Valid Alzheimer's Clinical Trials for the 21st Century
Monica Rivera-Mindt, Icahn School of Medicine at Mount Sinai, New York, NY (United States)
- 9.25 a.m. **SYMPOSIUM 2**
Donanemab in Early Symptomatic Alzheimer's Disease: Additional Insights from TRAILBLAZER-ALZ 2
John Sims¹, Dawn Brooks¹
¹Eli Lilly and Company - Indianapolis (United States)
- 10.05 a.m. Coffee break and poster session ☕
- 10.35 a.m. **LATE BREAKING ROUNDTABLE**
- 11.05 a.m. **ORAL COMMUNICATIONS**
- 11.05 a.m. **OC1 - Clinical effects of Lewy body pathology in clinically unimpaired and cognitively impaired individuals**
Oskar Hansson¹, Sebastian Palmqvist¹, Piero Parchi²
¹Lund University - Lund (Sweden), ²University of Bologna - Bologna (Italy)
- 11.20 a.m. **OC2 - Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's disease**
Gemma Salvadó¹, Kanta Horie^{2,3,4}, Nicolas R Barthélemy^{2,3}, Jacob W Vogel^{1,5}, Alexa Pichet Binette¹, Charlie D Chen⁶, Brian A Gordon⁶, Tammie L S Benzinger^{6,7}, David M Holtzman^{3,7}, John C Morris^{3,7}, Shorena Janelidze¹, Rik Ossenkoppele^{1,8,9}, Suzanne E Schindler^{3,7}, Randall J Bateman^{2,3,7}, Oskar Hansson^{1,10}
¹Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), ²The Tracy Family SILQ Center, Washington University School of Medicine - St Louis (United States), ³Department of Neurology, Washington University School of Medicine - St Louis (United States), ⁴Eisai Inc. - Nutley (United States), ⁵Department of Clinical Science, Malmö, SciLifeLab, Lund University - Lund (Sweden), ⁶Department of Radiology, Washington University School of Medicine - St Louis (United States), ⁷Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine - St Louis (United States), ⁸Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands), ⁹Amsterdam Neuroscience, Neurodegeneration - Amsterdam (Netherlands), ¹⁰Memory Clinic, Skåne University Hospital - Malmö (Sweden)
- 11.35 a.m. **OC3 - The anti-amyloid beta "brain shuttle" antibody trontinemab rapidly reduces amyloid plaques in people with Alzheimer's disease**
Luka Kulic¹, Fabien Alcaraz¹, Annamarie Vogt¹, Carsten Hofmann¹, Philip Barrington², Maddalena Marchesi¹, Gregory Klein¹, Ruth Crony³, David Agnew³, João A. Abrantes¹, Silke Ahlers⁴, Paul Delmar¹, Iris Wiesel¹, Hanno Svoboda¹
¹Roche - Basel (Switzerland), ²TranScrip group - Wokingham (United Kingdom), ³Roche - Welwyn (United Kingdom), ⁴Excelya Germany GmbH - Mannheim (Germany)
- 11.50 a.m. **OC4 - Rapid detection of the earliest amyloid-related changes in memory consolidation: assessment of learning using daily digital testing**
Kate Papp¹, Roos Jutten¹, Daniel Soberanes¹, Emma Weizenbaum¹, Stephanie Hsieh¹, Cassidy Molinare¹, Rachel Buckley¹, Rebecca Betensky², Keith Johnson¹, Dorene Rentz¹, Reisa Sperling¹, Rebecca Amariglio¹
¹Harvard Medical School - Boston (United States), ²New York University - New York (United States)
- 12.05 a.m. **OC5 - Clinical Outcomes From a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects With Mild to Moderate Probable Alzheimer's Disease**
Christopher Reading¹, Clarence Ahlem¹, Joseph Palumbo¹, Nily Osman¹, Marcia Testa², Donald Simonson³
¹BioVie Inc. - Carson City (United States), ²Department of Biostatistics, Harvard T.H. Chan School of Public Health - Boston (United States), ³Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School - Boston (United States)
- 12.20 p.m. Lunch break and poster session

● Wednesday, OCTOBER 25



1.20 p.m LATE BREAKING SYMPOSIUM

2.00 p.m ORAL COMMUNICATIONS

2.00 p.m **OC6 - Plasma P-tau217 facilitates a two-phase screening approach for participant selection into anti-amyloid trials**
Niklas Mattsson-Carlgrén¹, Lyduine Collij^{1,2}, Alexa Pichet Binette¹, Rik Ossenkoppelle^{1,2}, Ruben Smith¹, Olof Strandberg¹, Sebastian Palmqvist¹, Erik Stomrud¹, Nicholas Ashton³, Kaj Blennow³, Shorena Janelidze¹, Oskar Hansson¹
¹Lund University - Lund (Sweden), ²Amsterdam UMC - Amsterdam (Netherlands), ³University of Gothenburg - Gothenburg (Sweden)

2.15 p.m **OC7 - Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Patients with Signs and Symptoms of Cognitive Impairment**
Will Canestaro¹, Randall Bateman², David Holtzman², Mark Monane³, Joel Braunstein³
¹University of Washington School of Pharmacy - Seattle (United States), ²Washington University School of Medicine - St Louis (United States), ³C2N Diagnostics - St Louis (United States)

2.30 p.m **OC8 - A phase 2b clinical trial of neflamapimod in dementia with Lewy bodies designed to confirm the efficacy results from phase 2a**
Niels D. Prins¹, Amanda Gardner², Hui-May Chu³, Kelly Blackburn², James E. Galvin⁴, John J. Alam²
¹Brain Research Center - Amsterdam (Netherlands), ²EIP Pharma Inc - Boston (United States), ³Anoixis Corporation - Natick (United States), ⁴University of Miami Miller School of Medicine - Boca Raton (United States)

2.45 p.m **OC9 - Accelerated β -amyloid plaque reduction in Alzheimer's disease combining aducanumab infusion with focused ultrasound blood-brain barrier opening**
Ali Rezaei¹, Pierre D'haese¹, Marc Haut¹, Manish Ranjan¹, Jeffrey Carpenter¹, Rashi Mehta¹, Kirk Wilhelmsen¹, Peng Wang¹, Victor Finomore¹, Sally Hodder¹
¹WVU Rockefeller Neuroscience Institute - Morgantown (United States)

3.00 p.m LATE BREAKING COMMUNICATIONS

3.45 p.m Coffee break and poster session 

4.15 p.m **KEYNOTE 3**
Alzheimer's Disease: The Drug Development Pipeline and Emerging Therapies
Jeffrey Cummings, University of Nevada Las Vegas (UNLV), Las Vegas, NV (United States)

4.40 p.m LATE BREAKING COMMUNICATIONS

5.25 p.m End of the Conference Day

● Thursday, OCTOBER 26

8.00 a.m. **POSTER WALKING TOUR** - Poster Hall

9.00 a.m. **Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease**
Chair and introduction: Howard Fillit, *Alzheimer's Drug Discovery Foundation, New York, NY (United States)*

9.15 a.m. **OC10 - Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease (REGEN-BRAIN®)**
Roberta Brinton¹, Gerson Hernandez¹, Claudia Lopez¹, Lon Schneider²
¹University of Arizona - Tucson (United States), ²University of Southern California - Los Angeles (United States)

9.30 a.m. **OC11 - Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in an ongoing Phase 1/2 AD study**
Terrence Fisher¹, Elizabeth Evans¹, Megan Boise¹, Vikas Mishra¹, Crystal Mallow¹, John Leonard¹, Eric Siemers², Raymond Turner³, Wendy Bond⁴, John Huffaker⁴, Maurice Zauderer¹
¹Vaccinex, Inc. - Rochester (United States), ²Siemers Integration LLC - Indianapolis (United States), ³Re-Cognition Health - Fairfax (United States), ⁴Neuropsychiatric Research Center of Southwest Florida - Fort Myers (United States)
Note: For authors, after J. Huffaker and before M. Zauderer, please add "and all the SIGNALAD study investigators"

9.45 a.m. **OC12 - Astrocyte reactivity biomarker for the populational enrichment of clinical trials in preclinical Alzheimer's disease**
Bruna Bellaver¹, Guilherme Povala¹, Pamela C.I. Ferreira¹, João Pedro Ferrari-Souza¹, Douglas Teixeira Leffa¹, Firoza Z. Lussier¹, Andrea L. Benedet², Nicholas J. Ashton², Eduardo R. Zimmer³, Henrik Zetterberg², Kaj Blennow², Ann Cohen¹, Thomas K. Karikari¹, Pedro Rosa-Neto⁴, Tharick A. Pascoal¹
¹University of Pittsburgh - Pittsburgh (United States), ²University of Gothenburg - Gothenburg (United States), ³Universidade Federal do Rio Grande do Sul - Porto Alegre (United States), ⁴McGill University - Montreal (United States)

10.00 a.m. **LATE BREAKING ORAL COMMUNICATIONS**

10.30 a.m. Coffee break and poster session 

11.00 a.m. **KEYNOTE 4**
Clinical Trials in Alzheimer's Disease Prevention
Sandrine Andrieu, *Toulouse University Hospital, Toulouse (France)*

11.25 a.m. **SYMPOSIUM 3**
What can we LEARN from the A4 Study? Associations among longitudinal cognitive, functional, biomarker and imaging outcomes
Reisa Sperling¹, Michael Donohue², Rema Raman², Keith Johnson³, Roy Yaari⁴, Karen Holdridge⁴, Michael Case⁴, John Sims⁴, Paul Aisen², on behalf of the Learn A4 Study
¹Brigham and Women's Hospital Harvard Medical School - Boston (United States), ²Alzheimer Therapeutic Research Institute, University of Southern California - San Diego (United States), ³Massachusetts General Hospital, Harvard Medical School - Boston (United States), ⁴Eli Lilly and Co. - Indianapolis (United States)

12.05 p.m. Lunch and poster session

1.00 p.m. **ROUNDTABLE 2**
Forging the Path Forward: Capitalizing on Recent Alzheimer's Momentum through Strategic Investments in Novel Therapeutics
Howard Fillit¹, Niranjan Bose², Philip Scheltens³, Laurence Barker⁴
¹Alzheimer's Drug Discovery Foundation - New York City (United States), ²Gates Ventures - Seattle (United States), ³EQT Life Sciences - Amsterdam (Netherlands), ⁴Dementia Discovery Fund - London (United Kingdom)

● Thursday,
OCTOBER 26



2.00 p.m

ORAL COMMUNICATIONS

2.00 p.m

OC15 - Stress Testing the CL concept: Evaluating Centiloid Stability to Tracer, Effective Image Resolution and Quantification Method

Mahnaz Shekari^{1,2,3}, David Váñez García⁴, Lyduine.E Collij⁴, Daniel Altomare⁵, Fiona Heeman⁴, Hugh Pemberton^{6,7}, Núria Roé Vellvé⁸, Santiago Bullich⁸, Christopher Buckley⁶, Andrew Stephens⁸, Gill Farrar⁶, Giovanni Frisoni⁵, William.e Klunk⁹, Frederik Barkhof^{4,7}, Juan Domingo Gispert^{1,2,10}

¹BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ²IMIM (Hospital del Mar Medical Research Institute) - Barcelona (Spain), ³Universitat Pompeu Fabra - Barcelona (Spain), ⁴Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ⁵Memory Center, University Hospitals and University of Geneva - Geneva (Switzerland), ⁶GE Healthcare Pharmaceutical Diagnostics, UK - Amersham (United Kingdom), ⁷University College London - London (United Kingdom), ⁸Life Molecular Imaging GmbH - Berlin (Germany), ⁹University of Pittsburgh - Pittsburgh (United States), ¹⁰Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, (CIBER-BBN) - Barcelona (Spain)

2.15 p.m

OC16 - End-to-end automated scoring of speech-based cognitive assessments for Alzheimer's Disease: A comparison with manual scoring in the AMYPRED-US and AMYPRED-UK studies

Jack Weston¹, Udeepa Meepegama¹, Caroline Skirrow¹, Michael Ropacki², Emil Fristed¹

¹Novoic - London (United Kingdom), ²Oryzon - Temecula (United States)

2.30 p.m

OC17 - Characterization of the synaptic blood marker β -synuclein in different stages of Alzheimer's disease and other dementias

Patrick Oeckl¹, Giovanni Bellomo², Lorenzo Barba³, Daniel Alcolea⁴, Anna L. Wojdala², Juan Fortea⁴, Alberto Lleó⁴, Lucilla Parnetti², Olivia Belbin⁴, Markus Otto³

¹Ulm University Hospital, Department of Neurology and DZNE Ulm - Ulm (Germany), ²Section of Neurology, Department of Medicine and Surgery, University of Perugia - Perugia (Italy), ³Department of Neurology, Martin-Luther-University of Halle-Wittenberg - Halle (saale) (Germany), ⁴Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain - Barcelona (Spain)

2.45 p.m

OC18 - Remote detection and characterization of cognitive performance trajectories in mild cognitive impairment and populations at-risk from the INTUITION brain health study

Monroe Butler¹, Roland Brown¹, Andrew Becker¹, Matt Hobbs¹, Paramita Saha-Chaudhuri¹, Joaquín Penalver-Andres¹, Daniel Roggen¹, Alf Scotland¹, Yuval Zabar¹, Richard Hughes¹, Hanson Lenyoun², Matt Bianchi², Audrey Gabelle¹, Shibeshih Belachew¹, The Intuition Scientific Study Committee¹

¹Biogen - Cambridge (United States), ²Apple - Cupertino (United States)

3.00 p.m

OC19 - Binding profiles of lecanemab and donanemab to different amyloid-beta species

Lars Lannfelt^{1,2}, Malin Johannesson¹, Patrik Nygren¹, Adeline Rachalski¹, Emily Button¹, Anne-Sophie Svensson¹, Eleni Gkanatsiou¹, Nicolas Fritz¹, Olof Zachrisson¹, Linda Söderberg¹, Christer Möller¹

¹BioArctic AB - Stockholm (Sweden), ²Department of Public Health/Geriatrics - Uppsala (Sweden)

3.15 p.m

ROUNDTABLE 3

What is meaningful enough for CMS to cover? – What is reasonable and necessary?

Chair: Lefkos Middleton, Imperial College – London (United Kingdom)

Discussants: Maria Carrillo¹, Ron Petersen², Lon Schneider³

¹Alzheimer's Association - Chicago, IL (United States), ²Mayo Clinic - Rochester, MN (United States), ³USC - Los Angeles (United States)

3.45 p.m

Coffee break and poster session



● Thursday, OCTOBER 26

4.15 p.m

ORAL COMMUNICATIONS

4.15 p.m

OC20 - Estimating Time-Saving Treatment Effects in Alzheimer's Clinical Trials: Exploring Alternative Approaches

Guoqiao Wang¹, Gary Cutter², Lon Schneider³, Whedy Wang⁴, Brian Mangal⁴, Yijie Liao⁵, Yan Li¹, Chenjie Xiong¹, Jorge Llibre-Guerra¹, Eric Mcdade¹, Randall Bateman¹

¹Washington University School of Medicine, St. Louis, MO - St Louis (United States), ²University of Alabama at Birmingham - Birmingham (United States), ³Keck School of Medicine, University of Southern California - Los Angeles (United States), ⁴Alector, Inc - San Francisco (United States), ⁵Asher Biotherapeutics - San Francisco (United States)

4.30 p.m

OC21 - The Potential for Time Savings in Early Alzheimer Clinical Trials

Lon Schneider¹, Guoqiao Wang², Richard Kennedy³, Gary Cutter³

¹Keck School of Medicine of USC - Los Angeles (United States), ²Washington University - Saint Louis (United States), ³University of Alabama, Birmingham - Birmingham (United States)

4.45 p.m

OC22 - Precision medicine analysis of heterogeneity in individual-level treatment response to beta-amyloid removal in early Alzheimer's disease

Menglan Pang¹, Audrey Gabelle¹, Paramita Saha-Chaudhuri¹, Willem Huijbers¹, Arie Gafson¹, Paul Matthews², Lu Tian³, Ivana Rubino¹, Richard Hughes¹, Carl De Moor¹, Shibeshih Belachew¹, Changyu Shen¹

¹Biogen - Cambridge (United States), ²Imperial College London - London (United Kingdom), ³Stanford University School of Medicine - Stanford (United States)

5.00 p.m

OC23 - Effects of an 18-month multimodal intervention on cognitive function (J-MINT PRIME Tamba): A randomized controlled trial

Yutaro Oki¹, Tohmi Osaki², Ryoko Kumagai³, Shunsuke Murata⁴, Haruhi Encho³, Hisafumi Yasuda¹, Rei Ono⁵, Hisatomo Kowa³

¹Department of Public Health, Kobe University Graduate School of Health Sciences - Kobe (Japan), ²Department of Occupational Therapy, Faculty of Rehabilitation, Kobe Gakuin University - Kobe (Japan), ³Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences - Kobe (Japan), ⁴Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center Research Institute - Suita (Japan), ⁵Department of Physical Activity Research, National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition - Ibaraki (Japan)

5.15 p.m

End of the Conference Day

● Friday, OCTOBER 27



8.00 a.m **POSTER WALKING TOUR** - Poster Hall

9.00 a.m **KEYNOTE 5**
What we have learned about ARIA in anti-amyloid antibody treatment in mice and the implications for AD clinical trials
Cynthia A. Lemere, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (United States)

9.25 a.m **LATE BREAKING ORAL COMMUNICATIONS**

10.00 a.m Coffee break and poster session ☕

10.30 a.m **ORAL COMMUNICATIONS**

10.30 a.m **OC24 - Alzheimer's Disease in Down Syndrome: Clinical Trials**

Michael Rafii¹

¹Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (United States)

10.45 a.m **OC25 - Risk of Incident Cognitive Impairment Using Stages of Objective Memory Impairment (SOMI) and Neuroimaging**

Kellen Petersen¹, Ali Ezzati², Bhargav Nallapu¹, Richard Lipton¹, Reisa Sperling³, Kathryn Papp³, Dorene Rentz³, Ellen Grober¹

¹Albert Einstein College of Medicine - Bronx (United States), ²University of California, Irvine - Irvine (United States), ³Harvard Medical School - Boston (United States)

11.00 a.m **OC26 - Quantitative Amyloid-PET in Real-World Practice: Lessons from the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study**

Renaud La Joie¹, Ehud Zeltzer¹, Nidhi Mundada¹, Ganna Blazhenets¹, Jhonny Mejia Perez¹, Daniel Schonhaut¹, Leonardo Iaccarino², Maria Carrillo³, Lucy Hanna⁴, Constantine Gatsonis⁴, Andrew March⁵, Barry Siegel⁶, Bruce Hillner⁷, Rachel Whitmer⁸, Gil Rabinovici¹

¹University of California, San Francisco - San Francisco, Ca (United States), ²Avid Radiopharmaceuticals - Philadelphia, Pa (United States),

³Alzheimer's Association - Chicago, Il (United States), ⁴Brown university - Providence, Ri (United States), ⁵American College of Radiology - Philadelphia, Pa (United States),

⁶Washington University School of Medicine in St. Louis - St. Louis, Mo (United States), ⁷Virginia Commonwealth University - Richmond, Va (United States), ⁸University of California, Davis - Davis, Ca (United States)

11.15 a.m **OC27 - Measuring Meaningful Benefit of Disease Modifying Treatment on Health-Related Resource Use**

Carolyn Zhu¹, Mary Sano¹

¹Icahn School of Medicine at Mount Sinai - New York, NY (United States)

11.30 a.m **OC28 - Establishing the validity of a novel electronic Clinical Dementia Rating (eCDR)**

Rachel Nosheny¹, Daniel Yen², Taylor Howell¹, Monica Camacho³, Krista Moulder², Miriam Ashford³, Ronald Petersen⁴, Nikki Stricker⁴, Erik Roberson⁵, Daniel Marson⁵, Walter Kukull⁶, Scott Mackin¹, Michael Weiner¹, John Morris², Yan Li²

¹UCSF - San Francisco (United States), ²Washington University - St. Louis (United States), ³Northern California Institute for Research and Education - San Francisco (United States),

⁴Mayo Clinic - Rochester (United States), ⁵University of Alabama at Birmingham - Birmingham (United States), ⁶University of Washington - Seattle (United States)

11.45 a.m **OC29 - AI-based enrichment tools substantially increase the efficiency of AD clinical trials**

Viswanath Devanarayan¹, Yuanqing Ye¹, Harald Hampel¹, Lynn Kramer¹, Michael Irizarry¹, Shobha Dhadda¹

¹Eisai Inc. - Nutley (United States)

12.00 p.m **OC30 - Timing of Biomarker Changes in Sporadic Alzheimer Disease in Estimated Years from Symptom Onset**

Yan Li¹, Daniel Yen¹, Rachel Hendrix¹, Brian Gordon¹, Sibonginkhosi Dlamini¹, Nicolas Barthelemy¹, Andrew Aschenbrenner¹,

Rachel Henson¹, Eric Mcdade¹, David Holtzman¹, Tammie Benzinger¹, John Morris¹, Randall Bateman¹, Suzanne Schindler¹

¹Washington University in St. Louis - St. Louis (United States)

● Friday, OCTOBER 27

- 12.15 p.m Lunch break and poster sessions
- 1.15 p.m **LATE BREAKING ORAL COMMUNICATIONS**
- 3.15 p.m **ORAL COMMUNICATIONS' FOCUS SESSION: Phase 1 Clinical Trials**
- 3.15 p.m **OC31 - RG6289, a new γ -secretase modulator for the treatment of Alzheimer's disease: Results from a phase I healthy volunteer study**
 Stefan Sturm ¹, Agnes Portron ¹, Annamarie Vogt ², Agnes Poirier ¹, Tianxu Yang ³, Adnan Mohamed Abdi ¹, Gwendlyn Kollmorgen ⁴, Cory Simmons ⁵, Kalbinder Mahil ⁶, Lothar Lindemann ², Karl-Heinz Baumann ², Thomas Mueggler ², Taner Vardar ⁷, Rosanna Tortelli ², Irene Gerlach ²
¹Pharmaceutical Sciences, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ³Product Development Safety Risk Management (PDS), F. Hoffmann-La Roche Ltd - Beijing (China), ⁴Roche Diagnostics GmbH - Penzberg (Germany), ⁵Product Development Data Sciences, F. Hoffmann-La Roche Ltd - Mississauga (Canada), ⁶Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Roche Products Limited - Welwyn (United Kingdom), ⁷Product Development Safety Risk Management (PDS), F. Hoffmann-La Roche Ltd - Basel (Switzerland)
- 3.25 p.m **OC32 - A phase 1a single ascending dose study of the safety, tolerability, and brain receptor occupancy of BMS-984923 in healthy older adults**
 Adam P Mecca ¹, Elaheh Salardini ¹, Jean-Dominique Gallezot ¹, Ryan S O'dell ¹, Juan Young ¹, Emma Cooper ¹, Meghan G Donahue ¹, Julia L Waszak ¹, Jeanine L May ¹, Joshua Spurrier ¹, Timothy R Siegert ², Richard E Carson ¹, Stephen M Strittmatter ^{1,2}, Christopher H Van Dyck ¹
¹Yale School of Medicine - New Haven (United States), ²Allyx Therapeutics, Inc. - New Haven (United States)
- 3.35 p.m **OC33 - A Phase 1 Study demonstrating safety, CNS target engagement and PBMC pharmacodynamic response to ASN51, a novel and orally administered O-GlcNAcase inhibitor**
 Ryan Schubert ¹, Bruno Permanne ¹, Rolf Pokorny ¹, Pearl Fang ¹, Vanessa Teachout ¹, Maud Nény ¹, Solenne Ousson ¹, Ruhi Ahmed ¹, Manfred Schneider ¹, Anna Quattropani ¹, Dirk Beher ¹
¹Asceneuron - Lausanne (Switzerland)
- 3.45 p.m **OC34 - E2511, a Novel TrkA Modulator, Engages its CNS Cholinergic Target in a Phase 1 Clinical Study**
 Satya Saxena ¹, Yuanqing Ye ¹, Kazunari Sasaki ¹, Takeo Kamakura ¹, Garth Ringheim ¹, Luigi Giorgi ¹, Natasha Penner ¹, Kanta Horie ¹, Viswanath Devanarayan ¹, Pallavi Sachdev ¹
¹Eisai Inc. - Nutley (United States)
- 3.55 p.m **OC35 - Mode of action, clinical phase Ib data in patients, and the phase II design of the orally available anti-prionic compound PRI-002 that disassembles A β oligomers into A β monomers**
 Dieter Willbold ¹, Nicoleta-Carmen Cosma ², Janine Kutzsche ¹, Dagmar Jürgens ³, Gerhard Tischler ³, Oliver Peters ²
¹FZ Jülich - Jülich (Germany), ²Charité - Berlin (Germany), ³Prinnovation - Leipzig (Germany)
- 4.05 p.m End of the conference



POSTER PRESENTATIONS
presented in Boston
and available on the CTAD23
digital platform

IN-PERSON POSTER PRESENTATION DAYS

All posters are available in Pdf format
at [all times](#) on the CTAD23 digital platform.

Wednesday, October 25 from 8 a.m to 6 p.m

THEME: Clinical Trials: Methodology	P001 to P030
THEME: Clinical Trials: Results	P031 to P045
THEME: New Therapies and Clinical Trials	P153 to P158
THEME: Beyond Amyloid and Tau	P193 to P204

Thursday, October 26 from 8 a.m to 6 p.m

THEME: Clinical Trials: Imaging	P046 to P063
THEME: Clinical Trials: Biomarkers including plasma	P064 to P097
THEME: Clinical Trials: Cognitive and Functional Endpoints	P098 to P117

Friday, October 27 from 8 a.m to 5 p.m

THEME: Cognitive assessment and clinical trials	P118 to P137
THEME: Behavioral disorders and clinical trials	P138 to P140
THEME: Health economics and clinical trials	P141 to P143
THEME: Epidemiology and clinical trials	P144 to P150
THEME: Animal Model	P151 to P152
THEME: Proof of Concept/Translational research	P159 to P178
THEME: Digital health/E-trials	P179 to P192

Listing of CTAD23 POSTERS

All posters are available in Pdf format
at all times on the CTAD23 digital platform.

Posters presented [remotely](#)
are indicated with this icon : 

THEME: Clinical Trials: Methodology	P001 to P030
THEME: Clinical Trials: Results	P031 to P045
THEME: Clinical Trials: Imaging	P046 to P063
THEME: Clinical Trials: Biomarkers including plasma	P064 to P097
THEME: Clinical Trials: Cognitive and Functional Endpoints	P098 to P117
THEME: Cognitive assessment and clinical trials	P118 to P137
THEME: Behavioral disorders and clinical trials	P138 to P140
THEME: Health economics and clinical trials	P141 to P143
THEME: Epidemiology and clinical trials	P144 to P150
THEME: Animal Model	P151 to P152
THEME: New Therapies and Clinical Trials	P153 to P158
THEME: Proof of Concept/Translational research	P159 to P178
THEME: Digital health/E-trials	P179 to P192
THEME: Beyond Amyloid and Tau	P193 to P204



THEME: Clinical Trials: Methodology

- P001** **Variation in the mini-mental state examination in subjects with suspected mild to moderate Alzheimer's disease: Implications for clinical trial designs**
 James Rock¹, Jessie Nicodemus-Johnson², Holly Wood², Fred Kim¹, Jongkyi Kim³, Yoon-Seok Chun³, Suzanne Hendrix²
¹AriBio - San Diego (United States), ²Pentara - Mill Creek (United States), ³AriBNC - Gyeonggi-Do (United States)
- P002** **Communicating Topline Trial Results to Participants and Study Partners in a Preclinical Alzheimer's Disease Study**
 Taylor Clanton¹, Joshua D. Grill², Jason Karlawish³, Karen Chilcott Holdridge⁴, Roy Yaari⁴, Rema Raman¹, Sarah Walter¹, Elizabeth Shaffer¹, Paula J. G. Cohen¹, Paul S. Aisen¹, Reisa A. Sperling⁵
¹Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), ²UC Irvine - Irvine (United States), ³University of Pennsylvania - Philadelphia (United States), ⁴Eli Lilly and Company - Indianapolis (United States), ⁵Department of Neurology, Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital - Boston (United States)
- P003** **Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer's disease**
 Robyn Moxon¹, Todd Feaster¹, Gopalan Sethuraman¹, Alyssa Carroll¹, Siew Tin Gan¹, Shane Ziemba¹, Kimber Price¹, Vladimir Skljarevski¹, Karen Sundell¹, Janice Hitchcock¹, Eric Siemers¹
¹Acumen Pharmaceuticals - Charlottesville (United States)
- P004** **Investigating Treatment Effect Heterogeneity in Data-Driven Subgroups of TOMMORROW**
 Cameron Shand¹, Neil Oxtoby¹
¹University College London - London (United Kingdom)
- P005** **How should the next generation of Alzheimer's Disease clinical trials be analyzed in the estimands framework? The GRADUATE I & II experience**
 Rachid Abbas¹, Nicola Voyle², Giuseppe Palermo¹, Geoff Kerchner¹, Christopher Lane², Angeliki Thanasopoulou¹, Janice Smith², Rachele Doody^{1,3}, Paul Delmar¹
¹F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²Roche Products Ltd - Welwyn Garden City (United Kingdom), ³Genentech, Inc. - South San Francisco (United States)
- P006** **Factors Influencing Older Adults' Intention to Participate in a Secondary Prevention Trial in Alzheimer's Disease**
 Emily Largent¹, Joshua Grill², Jason Karlawish¹, Amy Bleakley³
¹University of Pennsylvania - Philadelphia (United States), ²University of California, Irvine - Irvine (United States), ³University of Delaware - Newark (United States)
- P007** **Evaluation of machine learning models that predict Alzheimer's disease progression in observational studies and randomized clinical trials**
 Sofia Broomé¹, Shibeshih Belachew², Bastien Caba², Enrica Cavedo¹, Jonathan Dubois², Audrey Gabelle², Refaat Gabr², Arie Gafson², Despoina Ioannidou¹, Xiaotong Jiang², Yan Jin², Neil Oxtoby³, Menglan Pang², Nikos Paragios¹, Willem Huijbers²
¹TheraPanacea - Paris (France), ²Biogen - Cambridge (United States), ³Toybox Science - Mildenhall (United Kingdom)
- P008** **Study Design of POLARIS-AD, AR1001 Phase 3 Study in Early Alzheimer's Disease**
 Sharon Sha¹, SangYun Kim^{2,3}, Jeffrey Cummings⁴, Charlotte Teunissen⁵, David Greeley⁶, Monica Kim⁶, James Rock⁶, Fred Kim⁶, Jai Jun Choung⁶
¹Stanford University - Palo Alto (United States), ²Seoul National University College of Medicine - Seoul (Korea, Republic of), ³Seoul National University Bundang Hospital - Seoul (Korea, Republic of), ⁴University of Nevada, Las Vegas - Las Vegas (United States), ⁵Amsterdam University Medical Centers - Amsterdam (Netherlands), ⁶AriBio Co., Ltd - Seongnam (Korea, Republic of)
- P009** **Enrichment for clinical trial of early AD using combination of PHS and plasma p-tau181 as screening instruments**
 Xin Wang¹, Xinran Wang¹, Steven Edland¹, Iris Broce¹, Sarah Banks¹
¹University of California, San Diego - La Jolla (United States)
- P010** **Validating an automatic phone-based speech biomarker measuring cognition SB-C against PACC5 and MoCA in the Swedish H70 epidemiological cohort**
 Johannes Tröger¹, Fredrik Öhman², Elisa Mallick¹, Alexandra König¹, Johan Skoog², Anna Zettergren², Silke Kern², Simona Sacuiu², Michael Schöll², Nicklas Linz¹, Ingmar Skoog²
¹ki elements GmbH - Saarbrücken (Germany), ²Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg - Gothenburg (Sweden)
- P011** **A systematic review and meta-analysis of agitation trials in individuals with dementia: Are cognitive measures needed?**
 Heather Belanger¹, Kavita Gohil¹, Jeffrey Finman¹, Gary Kay¹
¹Cognitive Research Corporation (CRC), University of South Florida - St Petersburg (United States)
- P012** **Effects of Informant Replacement in Alzheimer's Disease Clinical Trials**
 Mikaela Nishida¹, Michelle Nuno², Joshua Grill¹, Daniel Gillen¹
¹University of California, Irvine - Irvine (United States), ²University of Southern California - Los Angeles (United States)
- P013** **Harnessing the power of continuous time: Learnings from recent large clinical trial data**
 Paul Delmar¹, Lars Lau Raket², John O'gorman³, Michael Donohue⁴
¹F. Hoffmann-La Roche Ltd. - Basel (Switzerland), ²Eli Lilly and Company, Indianapolis, USA - Indianapolis (United States), ³Biogen - Cambridge (United States), ⁴University of Southern California - San Diego (United States)
- P014** **Internet-based insomnia intervention to prevent cognitive decline: Use of Internet-based recruitment, intervention, and assessment methods**
 Meghan Mattos¹, Carol Manning¹, Wen You¹, Kirsten Macdonnell¹, Lee Ritterband¹
¹University of Virginia - Charlottesville (United States)

POSTER PRESENTATIONS

- P015 Exploring the Impact of Baseline Discordance Between Functional Scales in Early AD Clinical Trials**
Alan Kott¹, Xingmei Wang², David Miller²
¹Signant Health - Prague (Czech Republic), ²Signant Health - Blue Bell (United States)
- P016 A pragmatic, investigator-driven process for disclosure of amyloid PET scan results to ADNI4 research participants**
Claire Erickson¹, Jason Karlawish¹, Joshua Grill², Kristin Harkins¹, Susan Landau³, Ronald Petersen⁴, Paul Aisen⁵, Michael Weiner⁶, Emily Largent¹
¹University of Pennsylvania - Philadelphia (United States), ²University of California Irvine - Irvine (United States), ³University of California Berkeley - Berkeley (United States), ⁴Mayo Clinic - Rochester (United States), ⁵University of Southern California - San Diego (United States), ⁶University of California San Francisco - San Francisco (United States)
- P017 RG6289, a new γ -secretase modulator for the treatment of Alzheimer's disease: Dose selection for a phase II trial based on population PK/PD modeling**
Dominik Lott¹, Agnes Portron¹, Mizan Alam¹, Carina Cantrill¹, Ruth Croney², Fabien Alcaraz³, Rosa Maria Rodríguez Sarmiento⁴, Lothar Lindemann³, Lutz Mueller¹, Thomas Mueggler³, Taner Vardar⁵, Rosanna Tortelli³, Stefan Sturm¹, Irene Gerlach³
¹Pharmaceutical Sciences, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Roche Products Limited - Welwyn (United Kingdom), ³Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁴Medicinal Chemistry, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁵Product Development Safety Risk Management (PDS), F. Hoffmann-La Roche Ltd - Basel (Switzerland)
- P018 Recruitment Source, Eligibility, and Reason for Prescreen-Fail across Sex, Race & Ethnicity: A Preliminary Analysis of Prescreening Data from the AHEAD Study**
Dylan Kirn^{1,2}, Shunran Wang³, Joshua D. Grill⁴, Karin Ernstrom³, Akpewweoghene Ikoba², Emily Sprague¹, Gustavo Jimenez-Maggiora³, Elizabeth Shaffer³, Reisa Sperling^{1,5}, Rema Raman³
¹Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ²Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Charlestown (United States), ³Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), ⁴Institute for Memory Impairments and Neurological Disorders, University of California Irvine - Irvine (United States), ⁵Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)
- P019 Impact of recruitment methods on racial and ethnic diversity: results from the Davis Memory and Aging Cohort at Mass General Brigham**
Stephanie Moreno¹, Akpewweoghene Ikoba¹, Caitlyn Christiano¹, Juliana Aya Ussui Anzai¹, Andrea Roman¹, Dylan Kirn², Lenore Jackson-Pope¹, Martha Cecilia Muniz¹, Jasmee P. Chhatwal³, Seth A. Gale⁴, Gad A. Marshall⁴, Reisa A. Sperling⁴, Hyun-Sik Yang⁵, Dennis J. Selkoe⁴, Dorene M. Rentz⁶
¹Center for Alzheimer Research and Treatment, Brigham and Women's Hospital - Boston (United States), ²Department of Neurology, Brigham and Women's Hospital - Boston (United States), ³Department of Neurology, Mass General Hospital - Boston (United States), ⁴Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ⁵Department of Neurology, Brigham and Women's Hospital - Boston (United States), ⁶Center for Alzheimer Research and Treatment, Brigham and Women's Hospital - Boston (United States) - Boston (United States)
- P020 Improving Diverse Recruitment in an Early Phase Therapeutic AD trial through a Pre-screening Study, Apheleia-001**
Dawn Batchuluun¹, Katy Smith¹, Tamiko Magee-Rodgers¹, Leigh Zisko¹, John Dwyer¹, Jason Bork¹, Richard Mohs¹, Julie Schwartzbard², Anthony Bannon³, Shau Yu Lynch³, Christa Lee³, Danielle Mcgeeney³
¹Global Alzheimer's Platform Foundation - Washington (United States), ²Aventura Hospital and Medical Center - Aventura (United States), ³AbbVie, Inc. - North Chicago (United States)
- P021 On Adaptive Randomization in Time-to-Event Alzheimer's Disease Clinical Trials**
Navneet Hakhu¹, Joshua Grill¹, Daniel Gillen¹
¹University of California, Irvine - Irvine (United States)
- P022 Views and perceptions of amyloid imaging among racial and ethnic groups in a preclinical Alzheimer's disease trial**
Christina M. Magana-Ramirez¹, Gimarie Irizarry², Daniel L. Gillen^{1,3}, Joshua D. Grill^{2,3,4}
¹Department of Statistics, University of California, Irvine, California - Irvine (United States), ²Department of Neurobiology and Behavior, University of California, Irvine, California - Irvine (United States), ³Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California - Irvine (United States), ⁴Department of Psychiatry and Human Behavior, University of California, Irvine, California - Irvine (United States)
- P023 Application of the personalized medicine approach to a behavioral intervention study: the Internet-based Conversational Engagement Clinical Trial (I-CONNECT)**
Chao-Yi Wu¹, Kexin Yu², Steven Arnold¹, Sudeshna Das¹, Hiroko Dodge¹
¹Neurology, Massachusetts General Hospital, Harvard Medical School - Charlestown (United States), ²Neurology, Oregon Health & Science University - Portland (United States)
- P024 Understanding Non-progressors in Alzheimer's Disease Clinical Trials**
Shuang Wu¹, Jennifer Murphy¹, Wei Feng², Philip Montenigro¹, Ying Tian¹
¹Biogen - Cambridge (United States), ²Keros Therapeutics - Lexington (United States)
- P025 A Phase 2 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Confirm Safety and Efficacy of NA-831 in Combination with Aducanumab in Subjects with Early Alzheimer's Disease**
Lloyd Tran¹, Fern Vu¹, Markku Kurkinen¹
¹Biomed Industries, Inc. - San Jose
- P025B A Phase 3 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Confirm Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease**
Lloyd Tran¹, Fern Vu¹, Markku Kurkinen¹
¹Biomed Industries, Inc. - San Jose (United States)

POSTER PRESENTATIONS

Poster presentations presented [remotely](#)

are indicated with this icon :



- P026 **Simulating Covariate-Adaptive Randomization Strategies in Alzheimer's Disease Clinical Trials**
Charlene Flournoy¹, Rema Raman¹, Paul Aisen¹, Michael Donohue¹
¹USC Alzheimer's Therapeutic Research Institute - San Diego (United States)
- P027 **Persistence Pays - The Relationship Between Repeated Reschedule Attempts and Eventual Attendance and Screening Rates**
Sarah Starling¹, Gabriela Munoz¹, Paul Sablone¹, Miriam Evans¹, Stephanie Rutrick¹
¹Adams Clinical - Watertown (United States)
- P028 **Methodologies that Support the Identification of Disease Modifying Therapies Which Are a Radical Shift from Short Acting Symptomatic Treatments: Owing Instead of Renting Our Treatment Effects**
Suzanne Hendrix¹, Craig Mallinckrodt¹, Samuel Dickson¹
¹Pentara - Salt Lake City (United States)
- P029 **The time machine: how converting treatment effects to time savings will change the world**
Samuel P. Dickson¹, Benjamin A. Haaland¹, Joshua Christensen¹, Matthew Morgan¹, Craig H. Mallinckrodt¹, Suzanne B. Hendrix¹
¹Pentara Corporation - Salt Lake City (United States)
- P030 **Why your AD clinical trial might succeed (the right reasons and the wrong ones)**
Kent Hendrix¹, Suzanne Hendrix¹, Samuel Dickson¹
¹Pentara - Salt Lake City (United States)

THEME: Clinical Trials: Results



- P031 **Combined exercise and cognitive interventions for adults with mild cognitive impairment and dementia: A systematic review and network meta-analysis**
Dandan Xue¹, Polly W.c. Li¹, Doris S.f. Yu¹, Rose S.y. Lin², Yuewen Lao³
¹School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong - Hong Kong (Hong Kong), ²University of Rochester School of Nursing, New York, USA - New York (United States), ³Sir Run Run Shaw Hospital, Zhejiang University School of Medicine - Hangzhou (China)
- P032 **Planning the next generation of Alzheimer's Disease clinical trials using diverse patient-level database from the Critical Path for Alzheimer's Disease (CPAD) Consortium**
Sudhir Sivakumaran¹, Nicholas Cullen¹, Eileen Priest¹, Corissa Lau¹, Hazel White¹, Michael Irizarry², Klaus Romero¹, Yashmin Karten¹
¹Critical Path Institute - Tucson (United States), ²Eisai Inc. - Nutley (United States)
- P033 **Critical Path for Alzheimer's Disease (CPAD) Consortium: Data-Driven Solutions for Clinical Trial Design and Informed Decision Making**
Sudhir Sivakumaran¹, Nicholas Cullen¹, Corissa Lau¹, Eileen Priest¹, Hazel White¹, Michael Irizarry², Gregory Klein³, Klaus Romero¹, Antoine Leuzy^{1,4,5}, Yashmin Karten¹
¹Critical Path Institute - Tucson (United States), ²Eisai Inc. - Nutley (United States), ³F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁴Lund University - Malmo (Sweden), ⁵Enigma Biomedical USA - Knoxville (United States)
- P034 **AB1601 phase 2 study of ABvac40, an anti-Aβ40 vaccine, in patients with a-MCI and vm-AD: Safety, tolerability, immune response, neuropsychological assessment and biomarkers**
Jose Terencio^{1,2}, Elisabet Molina¹, María Pascual-Lucas¹, Ana María Lacosta¹, Jesús Canudas¹, María Montañes¹, José Antonio Allué¹, Leticia Sarasa¹, Noelia Fandos¹, Judith Romero¹, Sergio Castillo¹, Manuel Sarasa¹, Mercè Boada^{3,4}
¹Araclon Biotech-Grifols - Zaragoza (Spain), ²Grifols - Barcelona (Spain), ³Ace Alzheimer Center Barcelona - Barcelona (Spain), ⁴Universitat Internacional de Catalunya - Barcelona (Spain)
- P035 **Safety and Feasibility Trial of Dapagliflozin in Early Alzheimer's Disease**
Jeffrey Burns¹, Jill Morris¹, Eric Vidoni¹, Heather Wilkins¹, In-Young Choi¹, Phil Lee¹, Suzanne Hunt¹, Jonathan Mahnken¹, William Brooks¹, Rebecca Lepping¹, Peter Adany¹, Aditi Gupta¹, Russell Swardlow¹
¹University Of Kansas Alzheimer's Disease Center - Kansas City (United States)
- P036 **Phase 3 Clinical Studies in Alzheimer's and Parkinson's disease; Interim Analysis and FDA guidance for both indications**
Cheng Fang¹, Eve Damiano¹, Melissa Gaines¹, Michele Shaffer², Anne-Marie Nagy³, Laurie Sanders⁴, Maria Maccacchini¹
¹Annovis Bio - Berwyn (United States), ²Wuxi - Austin (United States), ³TFS - Lund (Sweden), ⁴DCRI - Durham (United States)
- P037 **Safety, tolerability, and pharmacokinetics findings in a Phase 1 single dose study of donanemab in healthy Chinese participants**
Yimin Cui¹, Rihan Wu², Ivelina Gueorguieva³, Chenxi Qian², Junyu Xu¹
¹Peking University First Hospital - Beijing (China), ²Eli Lilly and Company - Shanghai (China), ³Eli Lilly and Company - Bracknell (United Kingdom)
- P038 **Safety of higher doses of gantenerumab in the open-label extension of the dominantly inherited Alzheimer's Network trials unit (DIAN-TU-001 trial)**
Jorge Llibre-Guerra¹, Nelly Joseph-Mathurin¹, Yan Li¹, Guoqiao Wang¹, Andrew Aschenbrenner¹, Xiong Chengjie¹, Brian Gordon¹, Janice Hitchcock², Richard Perrin¹, Carsten Hofmann³, Jakub Wojtowicz⁴, Atri Alireza⁵, Eric Mcdade¹, Randall Bateman¹, David Clifford¹
¹Washington University School Of Medicine In St.louis - St. Louis (United States), ²Hitchcock Regulatory Consulting, Inc - St. Louis (United States), ³Roche Innovation Center Basel - Basel (Switzerland), ⁴F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁵Banner Sun Health Research Institute - Sun, Arizona (United States)

POSTER PRESENTATIONS

- P039** **A Single Ascending Dose Study of ABBV-916, an Anti-Amyloid Antibody, in Healthy Volunteers**
Sagar Bachhav¹, Hana Florian², Joey Boiser³, Yamin Wang⁴, Dee-Dee Shiller¹, Shau Yu Lynch², Ole Graff², Hao Xiong¹
¹Clinical Pharmacology, AbbVie Inc - North Chicago (United States), ²Neuroscience Clinical Development, AbbVie Inc - North Chicago (United States), ³Pharmacovigilance and Patient Safety, AbbVie Inc - North Chicago (United States), ⁴Statistics, AbbVie Inc - North Chicago (United States)
- P040** **Efficacy of anti-amyloid- β monoclonal antibody therapy in prodromal versus mild dementia due to Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials**
Julyana Dantas¹, Pedro Romeiro², Caroline Dagostin³, Nicole Felix⁴, Denilsa Navalha⁵, Antonio Mutarelli⁶, Paulo Caramelli⁷, Sávio Batista⁸, Larissa Teixeira⁹
¹Federal University of Rio Grande do Norte - Natal (Brazil), ²University Center Tiradentes - Maceió (Brazil), ³University of the Extreme South of Santa Catarina - Criciúma (Brazil), ⁴Federal University of Campina Grande - Campina Grande (Brazil), ⁵Eduardo Mondlane University - Maputo (Mozambique), ⁶Federal University of Minas Gerais - Belo Horizonte (Brazil), ⁷Behavioral and Cognitive Neurology Unit, Federal University of Minas Gerais - Belo Horizonte (Brazil), ⁸Universidade Federal do Rio de Janeiro - Rio de Janeiro (Brazil), ⁹Universidade Federal de Campina Grande - Campina Grande (Brazil)
- P041** **High adherence and tolerability of a sensory stimulation system in a 6-month sham-controlled clinical trial in Alzheimer's disease**
Chandran V Seshagiri¹, Zach Malchano¹, Alyssa Boasso¹, Mihály Hajós¹, Evan Hempel¹, Kahlil G Saikali¹, Brent Vaughan¹, Ralph Kern¹
¹Cognito Therapeutics - Cambridge (United States)
- P042**
- P043** **Effect of ALZ-801 (Valiltramiprosate), an Oral Inhibitor of Amyloid Oligomer Formation, on Plasma Biomarkers, Volumetric Brain Imaging Biomarkers, and Clinical Outcomes of Alzheimer's Disease: 12-Month Results of Phase 2 Biomarker Study in Early AD APOE4 Carrier Subjects**
John Hey¹, Susan Abushakra¹, Philip Scheltens², Jakub Hort³, Katerina Sheardova^{4,5}, Ladislav Pazdera⁶, Niels Prins⁷, Sterre Rutgers⁷, Paul Dautzenberg⁷, Jeremy Yu¹, Patrick Kesslak¹, Luc Bracoud⁸, Aidan Power¹, Joyce Suhy⁸, Martin Tolar¹
¹Alzheon - Framingham (United States), ²Amsterdam University Medical Centers, Alzheimer Center - Amsterdam (Netherlands), ³Charles University Department of Neurology - Brno (Czech Republic), ⁴Memory Center, St. Anne University Hospital - Brno (Czech Republic), ⁵International Clinical Research Center - Brno (Czech Republic), ⁶Vestra Research Clinics - Rychnov And Kněžnou (Czech Republic), ⁷Brain Research Center - Den Bosch (Netherlands), ⁸Clario, Inc. - San Mateo (United States)
- P044** **Safety and pharmacokinetics of multiple ascending doses of E2511, a novel TrkA allosteric modulator, in healthy volunteers**
Natasha Penner¹, Nancy Hall¹, Cuiyuan Cai², Masaki Mikamoto², Jagadeesh Aluri¹, Takuya Yagi¹, Julia Chang¹, Ali Ardati¹, Steve Hersch¹, Luigi Giorgi³, Larisa Reyderman¹
¹Eisai - Nutley (United States), ²Eisai - Tsukuba (Japan), ³Eisai - Hatfield (United Kingdom)
- P045**

THEME: Clinical Trials: Imaging

- P046** **Brain structure-allelic associations and networks in Alzheimer's disease**
Seokwoo Moon¹
¹KONKUK UNIVERSITY CHUNGJU HOSPITAL - Chungju (Korea, Republic of)
- P047** **Impact of anodal transcranial direct current stimulation on white matter microstructure integrity in mild cognitive impairment patients according to effect modifiers as risk factors for Alzheimer's disease**
Dong Woo Kang¹
¹Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)
- P048** **Measuring changes in longitudinal Tau-PET with [18F]MK-6240: group-level vs individualized ROIs definition**
Nick Sidorenko¹, Matteo Tonietto¹, Antoine Leuzy², Gregory Klein¹
¹Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²Clinical Memory Research Unit, Department of Clinical Sciences, Lund University - Malmö (Sweden)
- P049** **Regional A β -tau interactions can predict individual-level time periods of the optimal therapeutic window for amyloid-lowering treatments**
Gillwan Lim¹, Hanna Cho², Chul Hyoung Lyoo², Joon-Kyung Seong^{1,3,4,5}, Wha Jin Lee¹, ADNI: Alzheimer's Disease Neuroimaging Initiative⁶
¹NeuroXT - Seoul (Korea, Republic of), ²Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), ³School of Biomedical Engineering, Korea University - Seoul (Korea, Republic of), ⁴Department of Artificial Intelligence, Korea University - Seoul (Korea, Republic of), ⁵Interdisciplinary Program in Precision Public Health, Korea University - Seoul (Korea, Republic of), ⁶Alzheimer's Disease Neuroimaging Initiative - Los Angeles (United States)
- P050** **Utility of [18F]PI-2620 PET in clinical trials: insights into tau pathology deposition in Down Syndrome**
Isabel Barroeta¹, Jordi Pegueroles¹, Victor Montal¹, Mateus Rozalem¹, Alejandra Morcillo¹, Sara Zsadaný¹, Lidia Vaque¹, Bessy Benejam¹, Laura Videla¹, Maria Carmona-Iraqui¹, Alexandre Bejanin¹, Valle Camacho², Albert Flotats², Alberto Lleo¹, Juan Fortea¹
¹Unidad de Memoria, Servicio de Neurología, Institut d'Investigacions Biomèdiques Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona - Barcelona (Spain), ²Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain - Barcelona (Spain)



- P051 Automated brain MRI segmentation using a novel AI-based method**
 Thomas Cajgfinger¹, Joël Schaerer¹, Po-Han Chen², Chris Conklin³, Madhura Ingalhalikar³, David Scott⁴, Joyce Suh⁴, **Luc Bracoud¹**
¹Clario - Lyon (France), ²Clario - Estenfeld (Germany), ³Clario - Philadelphia (United States), ⁴Clario - San Mateo (United States)
- P052 Assessing the Relationship Between Central Cholinergic Integrity and Amyloid Accumulation in Individuals with Down Syndrome Using [18F]-FE0BV and [11C]-PiB PET: Preliminary Data**
Jason K. Russell¹, Alexander C. Conley¹, Brian D. Boyd¹, Rachel Schlossberg¹, Adam J. Rosenberg², Lealani Mae Y. Acosta¹, Michael S. Rafii³, Sepideh Shokouhi¹, Paul A. Newhouse^{1,4}
¹Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center - Nashville (United States), ²Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center - Nashville (United States), ³Alzheimer's Therapeutic Research Institute and Department of Neurology, Keck School of Medicine, University of Southern California - San Diego (United States), ⁴Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System - Nashville (United States)
- P053 Efficacy of repetitive transcranial magnetic stimulation to improve memory in older adults with TBI**
Maheen Adamson¹
¹Stanford University/VA Palo Alto - Alameda (United States)
- P054 Cerebral Amyloid Angiopathy in APOE4/4 Homozygotes with Alzheimer's Disease: Baseline Characteristics of Subjects Enrolled in APOLLOE4 Phase 3 Trial of Oral ALZ-801 in Early AD**
 Rosalind McLaine¹, Susan Abushakra¹, Earvin Liang¹, Jerome Barakos², Aidan Power¹, David Watson³, Emer Macsweeney⁴, Anton Porsteinsson⁵, Joyce Suh⁶, John Hey¹, Martin Tolar¹
¹Alzheon, Inc. - Framingham (United States), ²California Pacific Medical Center & Clario - San Francisco (United States), ³Alzheimer's Research and Treatment Center - Wellington (United States), ⁴Re:Cognition Health - London (United Kingdom), ⁵University of Rochester School of Medicine and Dentistry - Rochester (United States), ⁶Clario - San Mateo (United States)
- P055 Changes in cortical microstructure in brain regions associated with cognitive status and disease duration after short-term treatment with XPro1595 for Alzheimer's disease**
 Parris Pope¹, Christopher Barnum¹, Raymond Tesi¹, Ged Ridgway², Mario Torso², Steven Chance²
¹INmune Bio, Inc. - Boca Raton (United States), ²Oxford Brain Diagnostics - Oxford (United Kingdom)
- P056 Association of cholinergic integrity to age, amyloid, cortical volume and cognitive performance in healthy postmenopausal women using [18F]-FE0BV PET**
Alexander Conley¹, Jason Russell¹, Brian Boyd¹, Tonnar Castellano¹, Adam Rosenberg², Brittany Bosko¹, Julie Dumas³, Paul Newhouse^{1,4}
¹Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center - Nashville (United States), ²Department of Radiology, Vanderbilt University Medical Center - Nashville (United States), ³Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont Larner College of Medicine - Burlington (United States), ⁴Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System - Nashville (United States)
- P057 Real-world implementation of patient stratification with faster cognitive decline using MRI-based prediction of regional tau positivity**
Yeong-Hun Song¹, Wha Jin Lee², Joon-Kyung Seong¹
¹Korea University - Seoul (Korea, Republic of), ²NeuroXT - Seoul (Korea, Republic of)
- P058 Association of amyloid PET burden with longitudinal cognitive decline in a heterogeneous Alzheimer's disease research cohort**
Emily Johns¹, Kyan Younes¹, Shubhabrata Mukherjee², Christina B. Young¹, Jesse Mez³, Timothy J. Hohman⁴, Duygu Tosun⁵, Sarah Biber⁶, Walter A. Kukull⁶, Paul Crane², Elizabeth C. Mormino¹
¹Department of Neurology and Neurological Sciences, Stanford University - Palo Alto (United States), ²Department of Medicine, The University of Washington - Seattle (United States), ³Department of Neurology, Boston University - Boston (United States), ⁴Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center - Nashville (United States), ⁵Department of Radiology and Biomedical Imaging, University of California, San Francisco - San Francisco (United States), ⁶Department of Epidemiology, National Alzheimer's Coordinating Center, University of Washington - Seattle (United States)
- P059 Stress-Testing the Centiloid Concept: Validation of the Between-Tracer Accuracy of the Centiloid Method in an Independent Cohort**
Juan Domingo Gispert^{1,2,3}, David Vázquez García⁴, Lyduine.e Collij⁴, Mahnaz Shekari^{1,2,5}, Lucca Presotto^{6,7}, Richard Manber⁷, Robin Wolz^{7,8}, Henrik Zetterberg^{9,10,11,12}, Kaj Blennow^{13,14}, Andrew Stephens¹⁵, Gill Farrar¹⁶, Pieter-Jelle Visser^{17,18,19}, Craig Ritchie²⁰, Frederik Barkhof^{4,21}
¹BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain - Barcelona (Spain), ²IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain - Barcelona (Spain), ³Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, (CIBER-BBN), Barcelona, Spain - Barcelona (Spain), ⁴Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117, Amsterdam, Netherlands & - Amsterdam (Netherlands), ⁵Universitat Pompeu Fabra, Barcelona, Spain - Barcelona (Spain), ⁶University of Milano-Bicocca - Milan (Italy), ⁷IXICO, London, UK - London (United Kingdom), ⁸Imperial College, London, UK - London (United Kingdom), ⁹Dementia Research Institute, University College London, London, UK - London (United Kingdom), ¹⁰Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK - London (United Kingdom), ¹¹Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China - Hong Kong (China), ¹²Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden - Gothenburg (Sweden), ¹³Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden - Gothenburg (Sweden), ¹⁴Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden - Mölndal (Sweden), ¹⁵Life Molecular Imaging GmbH, Berlin, Germany - Berlin (Germany), ¹⁶GE Healthcare Pharmaceutical Diagnostics, UK - Amersham (United Kingdom), ¹⁷Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHENS), Maastricht University, Maastricht, Netherlands - Maastricht (Netherlands), ¹⁸Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, Amsterdam University Medical Center, VU Medical Center, Amsterdam, Netherlands - Amsterdam (Netherlands), ¹⁹Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institute, Stockholm, Sweden - Stockholm (Sweden), ²⁰Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK - Edinburgh (United Kingdom), ²¹Institute of Neurology and Centre for Medical Image Computing, University College London, UK - London (United Kingdom)

POSTER PRESENTATIONS

- P060** **Estimating the time between Amyloid- and tau-PET positivity: Implications for Alzheimer's Disease Prevention trials**
Alexis Moscoso¹, Fiona Heeman¹, Tora Dunås¹, Michael Schöll¹
¹Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg - Gothenburg (Sweden)
- P061** **A Novel Tau Staging Scheme Using [18F]MK-6240 PET Visual Read Extent Scores**
Eddie Stage¹, Dustin Wooten¹, John Seibyl², Nicholas Seneca¹, Anthony Bannon¹, Hana Florian¹, Robert Comley¹, Qi Guo¹
¹AbbVie - North Chicago (United States), ²Institute for Neurodegenerative Disorders - New Haven (United States)
- P062** **Cortical microstructural changes associated with RBANS scores in cognitively unimpaired and MCI in the European Prevention of Alzheimer's Dementia (EPAD) study**
Mario Torso¹, Ged Ridgway¹, Michele Valotti¹, Ian Hardingham¹, Steven Chance^{1,2}
¹Oxford Brain Diagnostics - Oxford (United Kingdom), ²for the European Prevention of Alzheimer's Dementia (EPAD) Consortium
- P063** **Amyloid PET Scan Reads in IDEAS – Comparison of Local Clinician and Expert Reads**
Charles Windon¹, Barry Siegel², Maria Carrillo³, Constantine Gatsonis⁴, Lucy Hanna⁵, Bruce Hillner⁶, Andrew March⁷, Rachel Whitmer⁸, Anupa Arora⁹, Santiago Bullich¹⁰, Christopher Buckley¹¹, Paul Sherwin¹¹, Gil Rabinovici¹
¹Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco - San Francisco (United States), ²Mallinckrodt Institute of Radiology, Washington University in St Louis - St. Louis (United States), ³Alzheimer's Association - Chicago (United States), ⁴Department of Epidemiology and Biostatistics, Brown University School of Public Health - Providence (United States), ⁵Center for Statistical Sciences, Brown University School of Public Health - Providence (United States), ⁶Department of Medicine, Virginia Commonwealth University - Richmond (United States), ⁷American College of Radiology - Reston (United States), ⁸Department of Public Health Sciences, University of California, Davis - Davis (United States), ⁹Avid Radiopharmaceuticals - Philadelphia (United States), ¹⁰Life Molecular Imaging GmbH - Berlin (Germany), ¹¹GEHC - Massachusetts (United States)

THEME: Clinical Trials: Biomarkers including plasma

- P064** **The ViewMind AI Solution (VIMAS) detects and characterises neurocognitive decline along the Alzheimer's disease continuum**
Mario A. Parra¹, Francisco Lopera Restrepo², Gerardo Fernandez³
¹ViewMind Neuroscientific Officer, Reader in Psychology at University of Strathclyde, Glasgow - Glasgow (United Kingdom), ²ViewMind Clinical Advisor, Grupo de Neurociencias de Antioquia, Colombia - Antioquia (Colombia), ³ViewMind Chief Scientific Officer - Bahia Blanca (Argentina)
- P065** **Predicting cognitive stage transition using p-tau181, Centiloid, and other measures**
Seong-Ho Koh¹, Hyuk Sung Kwon¹, Yongkyung Lee¹, Hyun-Jeung Yu², Seong Hye Choi², Hongil Kim¹
¹Hanyang University Guri Hospital - Guri (Korea, Republic of), ²Bundang Jesaeng Hospital - Seongnam (Korea, Republic of)
- P066** **Relationship between brain amyloid deposition and regional electroencephalogram abnormalities in older adults**
Woo Jung Kim¹, Jaesub Park²
¹Yonsei University College of Medicine - Yongin-Si, Gyeonggi-Do (Korea, Republic of), ²National Health Insurance Service Ilsan Hospital - Goyang-Si, Gyeonggi-Do (Korea, Republic of)
- P067** **Relationship between telomere shortening and early subjective depressive symptoms and cognitive complaints in older adults**
Seong-Ho Koh¹, Hyun-Jeung Yu², Kee Hyung Park³, Seong Hye Choi⁴
¹Department of Neurology, College of Medicine, Hanyang University - Guri (Korea, Republic of), ²Bundang Jesaeng Hospital - Seongnam (Korea, Republic of), ³Department of Neurology, College of Medicine, Gachon University Gil Medical Center - Incheon (Korea, Republic of), ⁴Department of Neurology, College of Medicine, Inha University Medical Center - Incheon (Korea, Republic of)
- P068** **Direct Comparison of Four Blood Plasma-Based Biomarkers in Preclinical Alzheimer's Disease**
Peter Snyder¹, Jessica Alber¹, Andreas Jeromin², Lauren Chaby², Stuart Portbury², Louisa Thompson³, Jennifer Strenger⁴, Ashley Price¹
¹The University of Rhode Island - Kingston (United States), ²ALZpath, Inc. - Carlsbad (United States), ³Alpert Medical School of Brown University - Providence (United States), ⁴Butler Hospital - Providence (United States)
- P069** **Blood RNAs as fluid biomarkers for the differentiation between Alzheimer's disease and dementia with Lewy bodies**
Katrin Beyer¹, Jorge Mena¹, David Adamuz¹, Dolores Vilas², Ispuerto Lourdes², Álvarez Ramiro², Pastor Pau²
¹Research Institute Germans Trias i Pujol - Badalona (Spain), ²Hospital Germans Trias i Pujol - Badalona (Spain)
- P070** **Systematic literature review of the clinical and non-clinical value of imaging and fluid biomarker testing to diagnose, identify and monitor patients with Alzheimer's Disease**
Salwa Masud¹, Helen Hu², Sreeranjani Menon¹, Miya Strait¹, Christian Siegfried¹, Elizabeth Somers², Catheline Plaideau¹
¹Veranex - Boston (United States), ²Eisai Inc. - Nutley (United States)
- P071** **Serum Tau-A and Tau-C levels and their association with cognitive impairment and dementia progression in a memory clinic derived cohort**
Tobias Melton Axelsen^{1,2,3}, Peter Høgh^{4,5}, Asger Bihlet⁶, Morten Asser Karsdal², Kim Henriksen², Steen Gregers Hasselbalch⁷, Anja Hviid Simonsen^{7,5}
¹Department of Biomedical Sciences, University of Copenhagen - Copenhagen (Denmark), ²Nordic Bioscience - Herlev (Denmark), ³Sanos Clinic, Herlev, Denmark - Herlev (Denmark), ⁴Regional Dementia Research Centre, Department of Neurology, Zealand University Hospital - Roskilde (Denmark), ⁵Department of Clinical Medicine, University of Copenhagen - Copenhagen (Denmark), ⁶NBCD - Søborg (Denmark), ⁷Danish Dementia Research Centre (DDRC), Department of Neurology, Rigshospitalet - Copenhagen (Denmark)
- P072** **Biomarker responses to gamma sensory stimulation in Alzheimer's disease patients assessed in HOPE clinical trial**
Mihaly Hajos¹, Monika Shpokayte¹, Celine Houser¹, Evan Hempel¹, Chandran Seshagiri¹, Alyssa Galley¹, Zach Malchano¹, Ralph Kern¹
¹Cognito Therapeutics - Cambridge (United States)



- P073** **A robust and specific ELISA for N-acetylated VAMP-2, a novel synaptic biomarker for Alzheimer's disease in CSF**
Charlotte De Rocker¹, Julie Goossens¹, Alba Cervantes Gonzalez², Alberto Lleo², Olivia Belbin², Eugene Vanmechelen³
¹ADx NeuroSciences - Gent(-Zwijnaarde) (Belgium), ²CIBERNED - Madrid (Spain), ³ADx NeuroSciences - 4.1 (Belgium)
- P074** **Alzheimer's disease and microbiota: the MICMALZ cohort**
Germain Ulysse Busto^{1,2}, Linda-Nora Mekki³, Sylvaine Artero³, Yves Dauvilliers^{4,2}, Audrey Gabelle¹, Karim Bennis^{1,2}, Sylvie Claeysen¹
¹Resource and Research Memory Center (CMRR), Department of Neurology, Montpellier University Hospital - Montpellier (France), ²University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), - Montpellier (France), ³The Institute of Functional Genomics (IGF), University of Montpellier, CNRS, INSERM, Montpellier, France - Montpellier (France), ⁴Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital - Montpellier (France)
- P075** **Proteomic Analysis of Plasma in a Phase 2 Clinical Trial in Alzheimer's Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812**
Britney Lizama¹, Eunah Cho¹, Duc Duong², Kiran Pandey³, Claire Williams¹, Anthony Caggiano¹, Nicholas Seyfried², Valentina Di Caro¹, Mary Hamby¹
¹Cognition Therapeutics, Inc - Pittsburgh (United States), ²Emory University School of Medicine - Atlanta (United States), ³Emtherapro, Inc. - Atlanta (United States)
- P076** **Associations between the NIH Toolbox Emotion Battery and Tau Pathology in Preclinical Alzheimer's Disease: Analysis of data from the multi-site ARMADA study**
Kexin Yu¹, Jennifer Gatchel², Emily Ho³, Steven Arnold⁴, Hiroko Dodge⁴
¹Layton Aging and Alzheimer's Disease Center, Department of Neurology, Oregon Health & Science University - Portland (United States), ²Department of Psychiatry, Massachusetts General Hospital/McLean Hospital, Harvard Medical School - Boston (United States), ³Department of Medical Social Sciences, Northwestern University - Evanston (United States), ⁴Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)
- P077** **CSF interferon-β is identified as the principal type of interferon in Alzheimer's disease**
Qiong Wang¹, Feng Gao¹, Yong Shen¹
¹Department of Neurology and Institute on Aging and Brain Disorders, 1st affiliated Hospital of USTC, - Hefei (China)
- P078**
- P079** **Pharmacodynamic Effects of Semorinab on Biomarkers of Tau, Synaptic Function, and Gliosis in a Phase 2 Trial of Mild-to-Moderate Alzheimer's Disease (Lauriet)**
Stephen Schauer¹, Balaz Toth¹, Julie Lee¹, Veronica Anania¹, Lee Honigberg¹, Kristin Wildsmith¹, Vidya Ramakrishnan¹, Felix Yeh¹, Michael Dolton¹, Sandra Sanabria Bohorquez¹, Edmond Teng¹, Cecilia Monteiro¹
¹Genentech - South San Francisco (United States)
- P080** **CSF proteomic insights into the mechanism of action of gamma sensory stimulation in Alzheimer's Disease**
Kiran Pandey¹, Annabelle Singer², Duc Duong³, James Lah³, Allan Levey³, Nicholas Seyfried³, Monika Spokayte⁴, Zach Malchano⁴, Mihaly Hajos⁴
¹Emtherapro, Inc. - Atlanta (United States), ²Georgia Tech - Atlanta (United States), ³Emory University - Atlanta (United States), ⁴Cognito Therapeutics - Cambridge (United States)
- P081** **Changes in the neurology related CSF proteome after short-term treatment with XPro1595 for Alzheimer's disease**
Parris Pope¹, Christopher Barnum¹, Raymond Tesi¹
¹Inmune Bio, Inc. - Boca Raton (United States)
- P082** **A biomarker to aid Alzheimer's disease staging: sTREM2 is decreased in Amyloid positive/Tau negative, yet increased once Tau aggregates leading to increased cognitive decline**
Rodrigo Canovas¹, Christopher J. Fowler², Stephanie Rainey-Smith^{3,4,5,6}, Margherita Carboni⁷, Ivonne Suridjan⁷, Gwendlyn Kollmorgen⁸, Chad Logan⁹, Vincent Dore^{1,10}, Jurgen Fripp¹¹, Colin L. Masters², Qiao-Xin Li², Steven J. Collins¹², Paul Maruff¹³, James D. Doecke¹¹
¹Australian E-Health Research Centre, CSIRO, Parkville-Melbourne, Vic (Australia), ²The University of Melbourne, The Florey Institute-Melbourne, Vic (Australia), ³Centre for Healthy Ageing, Murdoch University - Murdoch, Wa (Australia), ⁴Australian Alzheimer's Research Foundation, - Perth, Wa (Australia), ⁵University of Western Australia - Perth, Wa (Australia), ⁶Edith Cowan University, School of Medical and Health Sciences, Centre of Excellence for Alzheimer's Disease Research & Care-Joondalup, Wa (Australia), ⁷Roche Diagnostics International Ltd-Rotkreuz (Switzerland), ⁸Roche Diagnostics GmbH - Penzberg (Germany), ⁹Centralised & Point of Care Solutions, Roche Diagnostics GmbH-Penzberg (Germany), ¹⁰Department of Molecular Imaging & Therapy Austin Health-Melbourne, Vic (Australia), ¹¹Australian E-Health Research Centre, CSIRO-Brisbane, Qld (Australia), ¹²Department of Medicine & The Florey Institute, The University of Melbourne, Parkville-Melbourne, Vic (Australia), ¹³Cogstate Ltd-Melbourne, Vic (Australia)
- P083** **Sex Differences in Amyloid PET: A Secondary Analysis of the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study**
Maison Abu Raya¹, Ehud Zeltzer¹, Isabel Elaine Allen¹, Maria Carrillo², Constantine Gatsonis³, Lucy Hanna⁴, Bruce E Hillner⁵, Leonardo Iaccarino¹, Andrew March⁶, Nidhi Mundada¹, Jhony Mejia Perez¹, Barry A Siegel⁷, Rachel A Whitmer⁸, Renaud La Joie¹, Gil Rabinovici¹
¹University of California San Francisco - San Francisco (United States), ²Alzheimer Association - Usa (United States), ³Brown University - Providence, Rhode Island (United States), ⁴Brown University - Providence, Rhode Island (United States), ⁵VCU Health - Virginia (United States), ⁶American College of Radiology - Philadelphia (United States), ⁷Washington University in St. Louis - St. Louis (United States), ⁸UCDAVIS - Davis (United States)
- P084** **The mastermind of the Alzheimer's blood-based biomarkers: development of cutoffs and a visualization tool for use in clinical dementia practice**
Charlotte Teunissen¹, Inge M.W. Verberk¹, Jolien Jutte^{1,2}, Maurice Y. Kingma^{1,2}, Argonde C. Van Harten^{1,3}, Anouk Den Braber^{1,3}, Sinthujah Vigneswaran^{1,4}, Mariam Gouda³, Marie-Paule Van Engelen³, Afina W. Lemstra³, Yolande A.L. Pijnenburg³, Wiesje M. Van Der Flier^{3,5}, Martijn Schut², David Wilson⁶
¹Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ²Translational Artificial Intelligence laboratory, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ³Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, - Amsterdam (Netherlands), ⁴Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, - Amsterdam (Pays-Bas) - Amsterdam (Netherlands), ⁵Amsterdam Public Health, Methodology & Digital Health - Amsterdam (Netherlands), ⁶Quanterix - Billerica (United States)

POSTER PRESENTATIONS


- P085 AD risk genes for blood-brain barrier dysfunction**
Pieter Jelle Visser^{1,2,3}, Sven Van Der Lee¹, Charlotte Teunissen¹, Wiesje Vander Flier¹, Frode Berven⁴, Betty Tijms¹
¹Amsterdam UMC - Amsterdam (Netherlands), ²Maastricht University - Maastricht (Netherlands), ³Karolinska Institute - Stockholm (Sweden), ⁴University of Bergen - Norway (Netherlands)
- P086 MIP-1 α serum levels correlate alongside positive outcome of clinical endpoints in Alzheimer's Disease patients receiving plasma exchange with albumin replacement**
Carla Minguet¹, Ricardo Gonzalo¹, Ana Ortiz¹, Isabel Bravo¹, Laura Núñez¹, Agustin Ruiz^{2,3}, Óscar López⁴, Mercè Boada^{2,3}, Antonio Páez¹, Montserrat Costa¹
¹Grifols - Barcelona (Spain), ²Universitat Internacional de Catalunya, Ace Alzheimer Centre Barcelona - Barcelona (Spain), ³Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) - Madrid (Spain), ⁴University of Pittsburgh School of Medicine - Pittsburg (United States)
- P087 Proteomic Analyses in the 24-Week PEGASUS Trial Using the Olink Platform: Providing Insight Into the Biologic Activity of Sodium Phenylbutyrate and Taurursodiol in Alzheimer's Disease**
Nicholas Cullen¹, Ryan Miller², Marcelo Gutierrez², Rudolph E. Tanzi³, Lahar Mehta²
¹BioFINDER Group, Department of Clinical Sciences, Lund University - Lund (Sweden), ²Amylyx Pharmaceuticals, Inc. - Cambridge (United States), ³Department of Neurology, Genetics and Aging Research Unit, McCance Center for Brain Health, Massachusetts General Hospital, Harvard University - Boston (United States)
- P088 Statistical considerations for assessing the relationship between disease progression biomarkers and clinical endpoints in alzheimer's disease**
Tianle Chen¹, R.matthew Hutchison¹, Carrie Rubel¹, Jennifer Murphy¹, Jing Xie¹, Philip Montenegro¹, Wenting Cheng¹, Kyle Fraser¹, Gersham Dent¹, John O'gorman¹, Suzanne Hendrix², Oskar Hansson³, Paul Aisen⁴, Ying Tian¹
¹Biogen - Cambridge, Ma (United States), ²Pentara Corporation - Millcreek, Ut (United States), ³Lund University - Malmö (Sweden), ⁴University of Southern California - San Diego, Ca (United States)
- P089 Validation of clinical cutoffs for the beta-amyloid (A β 42), p-Tau181 and p-Tau181/A β 42 Roche Elecsys Generation 2 assays**
Joshua Bornhorst¹, Rebecca Deters¹, Jp Theobald¹, Alicia Algeciras-Schimmich¹
¹Mayo Clinic - Rochester (United States)
- P090 Structural and functional DMN preservation after 24 weeks of rTMS in Alzheimer's disease patients**
Giacomo Koch¹, Lucia Mencarelli¹, Mario Torso², Martina Assogna¹, Federico Giove¹, Emiliano Santarnecchi³, Emiliano Santarnecchi³
¹Santa Lucia Foundation IRCCS - Rome (Italy), ²Oxford Diagnostics - Oxford (United Kingdom), ³MGH - Boston (United States)
- P091 Effects of Oral ALZ-801 (Valiltramiprosate) on Core Plasma Biomarkers of Alzheimer's Disease (AD): Final 2-year Analysis of Phase 2 Biomarker Study in APOE4 Carriers with Early AD**
Susan Abushakra¹, John Hey¹, Kaj Blennow², Eric Reiman³, Jakub Hort⁴, Katerina Sheardova⁵, Niels Prins⁶, Sterre Rutgers⁶, Patrick Kesslak¹, Aidan Power¹, Martin Tolar¹
¹Alzheon - Framingham (United States), ²Gothenburg University, Institute of Neuroscience & Physiology & Neurochemistry Laboratory - Molndal (Sweden), ³Banner Alzheimer's Institute and University of Arizona - Arizona (United States), ⁴Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital - Brno (Czech Republic), ⁵International Clinic Research Center, St. Anne's University Hospital - Brno (Czech Republic), ⁶Brain Research Center - Amsterdam (Netherlands)
- P092 Associations Between Blood-Based Biomarkers and Amyloid PET measurements in Cognitively Unimpaired Presenilin 1 E280A Mutation and Non-Mutation Carriers from the API Autosomal Dominant Alzheimer's Disease Colombia Prevention Trial**
Vedanshi Bhargava^{*1}, Mike Malek-Ahmadi^{*2,3,4}, Francisco Lopera^{*5}, Silvia Rios-Romenets⁵, Eugenia Cardona⁵, Yakeel T Quiroz-Gaviria⁶, Jessica Langabaum², Pierre Tariot², Robert Alexander², Yi Su^{2,1,7}, Kewei Chen^{2,3}, Tobias Bittner⁸, David Clayton⁸, Rachele Doody⁸, Eric Reiman^{2,9,10,1}
¹University of Arizona College of Medicine Phoenix - Phoenix (United States), ²Banner Alzheimer's Institute - Phoenix (United States), ³University of Arizona College of Medicine Phoenix - Phoenix (United States), ⁴Arizona Alzheimer's Consortium - Phoenix (United States), ⁵Neurosciences Group of Antioquia, Universidad de Antioquia - Medellín (Colombia), ⁶Massachusetts General Hospital and Harvard Medical School - Boston (United States), ⁷Arizona Alzheimer's Consortium - Phoenix (United States), ⁸Genentech - San Francisco (United States), ⁹Translational Genomics Research Institute - Phoenix (United States), ¹⁰Arizona Alzheimer's Consortium - Phoenix (United States)
- P093 Plasma p-tau217 as a cost-effective surrogate biomarker for clinical trials across the AD continuum**
Pamela C Lukasewicz Ferreira¹, Bruna Bellaver¹, Guilherme Povala¹, Joao Pedro Ferrari-Souza¹, Firoza Z. Lussier¹, Douglas T. Leffa¹, Helmet Karim¹, Chang Hyung Hong², Hyun Woong Rho², Dana L. Tudorascu¹, Thomas K. Karikari¹, Beth E. Snitz³, Sang Joon Son², Tharick A Pascoal¹
¹Department of Psychiatry, School of medicine, University of Pittsburgh - Pittsburgh (United States), ²Department of Psychiatry, Ajou University School of Medicine - Sowon (Korea, Republic of), ³Department of Neurology, School of Medicine, University of Pittsburgh - Pittsburgh (United States)
- P094 Plasma biomarkers and longitudinal cognitive decline in non-demented Alzheimer's disease**
Karly Cody¹, Rebecca Langhough¹, Lianlian Du¹, Erin Jonaitis¹, Nathaniel Chin¹, Beckie Jeffers¹, Monica Vandenlangenberg¹, Sanjay Asthana¹, Kris Kirmess², Matthew Meyer², Kevin Yarasheski², Tim West², Tobey Betthausen¹, Sterling Johnson¹
¹Wisconsin Alzheimer's Disease Research Center, University of Wisconsin - Madison (United States), ²C2N Diagnostics - St. Louis (United States)
- P095 Cerebrospinal fluid cellular transcriptomics as biomarkers of central nervous system drug-target engagement of a peripherally administered vaccine in older adults with and without cognitive impairment (BCG-AD)**
Marc Weinberg^{1,2}, Mahesh Kodali^{1,2}, Rojashree Jayakumar¹, Denise L. Faustman¹, Sudeshna Das^{1,2}, Steven Arnold^{1,2}
¹Mass General Hospital - Boston, MA (United States), ²Harvard Medical School - Cambridge, Ma (United States)
- P096 Bio-Hermes study topline results: AB 42/40 and p-Tau 181/217 blood-based biomarkers compared to amyloid PET and CSF in a diverse, community-based population**
Douglas Bearegard¹, Richard Mohs¹, John Dwyer¹, Sarah Hollingshead¹, Jennifer Gaudio¹, Jason Bork¹, Diana Kerwin²
¹Global Alzheimer's Platform Foundation - Washington, Dc (United States), ²Kerwin Medical Center - Dallas (United States)

P097 **From clinical trials to routine use: a journey from development to commercialization of biofluid markers for Alzheimer's disease**
 Sylvain Lehmann¹
¹INM Inserm, University CHU Montpellier - Montpellier (France)

THEME: Clinical Trials: Cognitive and functional endpoints

P098 **Between-Country Comparisons of Quality of Life and Activities of Daily Living in Multinational Alzheimer's Disease Clinical Trials**
 Sayaka Machizawa¹, Erica Appleman¹, Jessica Stenclik¹, Andrei Iacob², Rujvi Kamat¹
¹Signant Health - Blue Bell (United States), ²Signant Health - Bucharest (Romania)

P099 **The Effect of Global Functioning on Participant and Study Partner Ratings of Quality of Life in Participants with Prodromal to Mild Alzheimer's Disease**
 Jessica Stenclik¹, Amanda Aedo¹, Sayaka Machizawa¹, Rujvi Kamat¹, Erica Appleman¹, Andrei Iacob¹
¹Signant Health - Blue Bell (United States)

 P100 **Blood pressure variability via ambulatory monitoring and risk for dementia in the SPRINT MIND trial**
 Isabel Sible¹, Daniel Nation²
¹University of Southern California - Los Angeles (United States), ²University of California Irvine - Irvine (United States)

P101 **Longitudinal resting-state EEG along the Alzheimer's disease continuum: the road to successful clinical trial implementation**
 Elliz P. Scheijbeler¹, Willem De Haan¹, Cornelis J. Stam¹, Jos W. R. Twisk¹, Alida A. Gouw¹
¹Amsterdam UMC location VUmc - Amsterdam (Netherlands)

P102 **The EEG as functional endpoint in AD trials**
 Willem De Haan^{1,2}, Elliz Scheijbeler^{1,2}, Alida Gouw^{1,2,3}, Cornelis Jan Stam^{4,2}
¹Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands), ²Amsterdam Neuroscience, Neurodegeneration, - Amsterdam (Netherlands), ³Clinical Neurophysiology and MEG Center, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, - Amsterdam (Netherlands), ⁴Clinical Neurophysiology and MEG Center, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands)

P103 **Rates of Progression in Patients with Alzheimer's Disease Depending on Apolipoprotein E Genotype and Concomitant Medications**
 Carina Wattmo¹
¹Cognitive Disorders Research Unit, Department of Clinical Sciences, Malmö, Lund University - Malmö (Sweden)

P104 **Effects of Melissa officinalis extract containing rosmarinic acid for Alzheimer's disease in human**
 Moeko Shinohara¹, Kenjiro Ono¹
¹Kanazawa University - Kanazawa (Japan)

P105 **TRAILBLAZER-ALZ 2: Heterogeneity in performance of clinical outcome assessments across geo-cultural areas**
 Giulia Tronchin¹, Wendy Wenyu Ye¹, Xiaojuan Mi², Alette M. Wessels¹
¹Eli Lilly and Company - Indianapolis (United States), ²TechData Services Company - King Of Prussia (United States)

P106 **Assessing 'true' non-progression rate in early Alzheimer's disease accounting for within-subject variation**
 Menglan Pang¹, Willem Huijbers¹, Audrey Gabelle¹, Arie Gafson¹, Richard Hughes¹, Shibeshih Belachew¹, Shen Changyu¹
¹Biogen - Cambridge (United States)

P107 **Video-based Assessment of Cognitive Frailty in Older Adults with Cognitive Impairment**
 Ram Kinker Mishra¹, Myeounggon Lee², Jaewon Beom², Mohammad Dehghan Rouzi³, Ashkan Vaziri¹, Bijan Najafi²
¹Ph.D. - Boston (United States), ²Ph.D. - Houston (United States), ³Master - Houston (United States)

P108 **Therapeutic drug monitoring for dose optimization in Alzheimer's disease and in dementia with Lewy bodies**
 Peter Høgh¹, Michael Fischer¹
¹Department of Neurology, Zealand University Hospital - Roskilde (Denmark)

P109 **Timing the change in the Pre-clinical Alzheimer's Cognitive Composite score with Amyloid-β in pre-clinical Alzheimer's Disease**
 Timothy Cox¹, Rosita Shishegar¹, Christopher Fowler², Stephanie Rainey-Smith^{3,4,5,6}, Hamid Sohrabi^{3,4}, Shaun Markovic^{3,4}, Vincent Dore^{1,7}, Pierrick Bourgeat⁸, Jurgen Fripp⁸, Ralph Martins^{6,9}, Victor Villemagne¹⁰, Colin Masters², Christopher Rowe^{2,7}, James Doecke⁸
¹Australian E-Health Research Centre, CSIRO - Parkville (Australia), ²The University of Melbourne, The Florey Institute - Melbourne (Australia), ³Centre for Healthy Ageing, Murdoch University - Murdoch (Australia), ⁴Australian Alzheimer's Research Foundation - Perth (Australia), ⁵University of Western Australia - Perth (Australia), ⁶Edith Cowan University, School of Medical and Health Sciences, Centre of Excellence for Alzheimer's Disease Research & Care - Perth (Australia), ⁷Department of Molecular Imaging & Therapy Austin Health - Melbourne (Australia), ⁸Australian E-Health Research Centre, CSIRO - Brisbane (Australia), ⁹Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University - Sydney (Australia), ¹⁰Department of Psychiatry, University of Pittsburgh School of Medicine - Pittsburgh (United States)

P110 **Impact of study partner type on primary endpoint variability in two phase 3 registration trials in mild-to-moderate Alzheimer's disease**
 Mary Ryan^{1,2,3}, Daniel Gillen^{1,2}, Joshua Grill^{1,4,5}
¹Institute for Memory Impairments and Neurological Disorders, UC Irvine - Irvine (United States), ²Department of Statistics, UC Irvine - Irvine (United States), ³Department of Biostatistics, Yale School of Public Health - New Haven (United States), ⁴Department of Psychiatry and Human Behavior, UC Irvine - Irvine (United States), ⁵Department of Neurobiology and Behavior, UC Irvine - Irvine (United States)

P111 **Effects of phytoncide inhalation on Stroop task performance in patients with mild cognitive impairment: an fNIRS pilot study**
 Do Hoon Kim¹, Seungchan Park¹, Jiheon Kim¹
¹Chuncheon Sacred Heart Hospital Hallym University College of Medicine - Chuncheon (Korea, Republic of)

POSTER PRESENTATIONS

- P112 **The use of composite z-scores in place of normative-based scaling to improve signal detection in clinical trials involving neurodegenerative diseases**
Erin Jacobs¹
¹WCG Clinical - Princeton (United States)
- P113 **The Expanded Brief Assessment of Cognition (BAC) for the Assessment of Cognitive Impairment in Mild Alzheimer's Disease**
Dorothee Schoemaker¹, Alexandra S. Atkins¹, Chelsea Abraham¹, Haley Evans¹, Matthew Welch¹, Brenda L. Plassman², Corrine Madsen², Nancy Sickel², Jan Sedway¹, Kathleen A. Welsh-Bohmer¹, Rich S.e. Keefe¹
¹WCG - Cary (United States), ²Duke University - Durham (United States)
- P114 **Standardized Implementation of Personalized Endpoints Following FDA's Draft Guidance 4 on Patient-Focused Drug Development: Goal Attainment Scaling in a Phase 2 Study of Xpro in Patients with Early Alzheimer's Disease**
Gunes Sevinc¹, Chere Chapman¹, Tara Lehner², Christopher Barnum², Judith Jaeger^{2,3,4}, Kenneth Rockwood^{1,5,6}
¹Ardea Outcomes - Nova Scotia (Canada), ²INmune Bio, Inc - Florida (United States), ³CognitionMetrics, LLC - Connecticut (United States), ⁴Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine - New York (United States), ⁵Division of Geriatric Medicine, Dalhousie University, - Nova Scotia (Canada), ⁶Geriatric Medicine Research Unit, Nova Scotia Health Authority, - Nova Scotia (Canada)
- P115 **Verbal Learning Over Five Days: Learning Curves, Age-Independence, and Sleep Sensitivity**
Alexander Kaula¹, Nicholas Taptiklis¹, Naim Sen¹, Francesca Cormack^{1,2}
¹Cambridge Cognition - Cambridge (United Kingdom), ²University of Cambridge - Cambridge (United Kingdom)
- P116 **A Meta-Analysis to Demonstrate the Incidence of Placebo Effect in Alzheimer's Disease and Mild Cognitive Impairment Trials: Mitigating for Impacts on Trial Endpoints**
Melissa Carbo¹, Madelyn Moberg¹, Rolana Avrumson¹
¹Worldwide Clinical Trials - Doylestown (United States)
- P117 **Capturing clinically meaningful change in Alzheimer's disease: the electronic Person Specific Outcome Measure approach**
Stina Saunders^{1,2}, Joyce Gomes-Osman^{1,3}, Ali Jannati^{1,4}, Sean Tobbyne¹, Jeff Pobst¹, Craig Ritchie^{5,6}, Saturnino Luz², Graciela Muniz-Terrera^{2,7}, Álvaro Pascual-Leone^{1,8}
¹Linus Health Inc - Boston (United States), ²University of Edinburgh - Edinburgh (United Kingdom), ³University of Miami Miller School of Medicine - Miami (United States), ⁴Harvard Medical School - Boston (United States), ⁵Scottish Brain Sciences - Edinburgh (United Kingdom), ⁶University of Edinburgh - Edinburgh (United Kingdom) - Edinburgh (United Kingdom), ⁷University of Ohio - Ohio (United States), ⁸Hebrew SeniorLife - Boston (United States)

THEME: Cognitive assessment and clinical trials

- P118 **The ViewMind AI Solution (VIMAS) addresses inequities and disparities in the assessment of dementia risk**
Mario A. Parra¹, Alfredis Gonzalez-Hernandez², Jasmin Bonilla-Santos³, Rodrigo A. Gonzalez-Montealegre², Dorian Yisela-Cala³, Gerardo Fernandez⁴
¹ViewMind Neuroscientific Officer, Reader in Psychology at University of Strathclyde, Glasgow - Glasgow (United Kingdom), ²Department of Psychology, Master programme of clinical Neuropsychology, Universidad Surcolombiana - Huila (Colombia), ³Department of Psychology, Universidad Cooperativa de Colombia - Huila (Colombia), ⁴ViewMind Chief Scientific Officer - Bahia Blanca (Argentina)
- P119 **Clinical Dementia Rating Scale (CDR®) domain scores differ by diagnosis in Hispanic and non-Hispanic White samples**
Giovanna Pilonieta¹, David Geldmacher¹
¹The University of Alabama at Birmingham - Birmingham (United States)
- P120 **Sex bias and the association of dementia lifestyle risk factors with superager status**
Matthew Mcphee¹, Larissa Mcketton², Annalise Laplume³, Angela Troyer^{1,4}, Nicole Anderson^{2,4,5}
¹Neuropsychology and Cognitive Health, Baycrest - Toronto (Canada), ²Rotman Research Institute, Baycrest Academy for Research and Education - Toronto (Canada), ³Douglas Research Centre, McGill University and Centre for Research at the Geriatrics Institute of the University of Montreal - Montreal (Canada), ⁴Department of Psychology, University of Toronto - Toronto (Canada), ⁵Department of Psychiatry, University of Toronto - Toronto (Canada)
- P121 **Objective Monitoring of Instrumental Activities of Daily Living in Dementia**
Ram Kinker Mishra¹, Myeounggon Lee², Adonay S. Nunes¹, Michele K. York², Mark E. Kunik², Ashkan Vaziri¹, Bijan Najafi²
¹Biosensics - Boston (United States), ²Baylor College of Medicine - Houston (United States)
- P122 **Errors in Clinical Dementia Rating administration and scoring: Identifying targets for intervention**
Ruji Kamat¹, Jacqueline Massa¹, Amanda Aedo¹, Gila Barbati¹, Sayaka Machizawa¹, Jessica Stenclik¹, Erica Appleman¹, Andrei Iacob¹
¹Signant Health - Blue Bell (United States)
- P123 **Leveraging AI methods to detect cognitive decline and dementia over the telephone: a promising new screening tool**
Catherine Diaz-Asper¹, Chelsea Chandler², R. Scott Turner³, Brigid Reynolds³, Brita Elvevåg⁴
¹Marymount University - Arlington (United States), ²University of Colorado, Boulder - Boulder (United States), ³Georgetown University - Washington Dc (United States), ⁴University of Tromsø - the Arctic University of Norway - Tromsø (Norway)
- P124 **Influence of COVID-19 pandemic to self-perceived memory decline: contribution to cognitive change one-year later**
Kenichiro Sato^{1,2}, Yoshiki Niimi², Ryoko Ihara³, Kazushi Suzuki⁴, Atsushi Iwata³, Takeshi Iwatsubo^{1,2}
¹University of Tokyo - Tokyo (Japan), ²University of Tokyo Hospital - Tokyo (Japan), ³Tokyo Metropolitan Geriatric Medical Center Hospital - Tokyo (Japan), ⁴National Defense Medical College - Saitama (Japan)

- P125 Nili: Digital Health Solution for Dementia Care Coordination and Management**
 Ram Kinker Mishra ¹, Myeounggon Lee ^{2,3}, Michele K. York ³, Mark E. Kunik ^{4,5}, Bijan Najafi ^{2,3}, **Ashkan Vaziri** ¹
¹BioSensics LLC - Newton (United States), ²Department of Surgery, Baylor College of Medicine - Houston (United States), ³Neurology and Psychiatry & Behavioral Sciences, Baylor College of Medicine - Houston (United States), ⁴Menninger Department of Psychiatry and Behavioral Science, Baylor College of Medicine, - Houston (United States), ⁵Michael E. DeBakey Veterans Affairs Medical Center - Houston (United States)
- P126 Using Speech Biomarkers for Detection and Monitoring of Cognitive Decline**
 Adonay S. Nunes ¹, Gozde Cay ², Myeounggon Lee ², Mohammad Dehghan Rouzi ², Nesreen El-Refaei ², Anmol Momin ², Ram Kinker Mishra ¹, Bijan Najafi ², **Ashkan Vaziri** ¹
¹BioSensics LLC - Boston (United States), ²Interdisciplinary Consortium on Advanced Motion Performance (iCAMP), Michael E. DeBakey Department of Surgery, Baylor College of Medicine - Houston (United States)
- P127 Validation of a TICS-m cutoff score for identification of cognitive impairment during telephone pre-screening assessment**
Eric Fischer ¹, Abigail O'Connell ², Sarah Gaussoin ³, Samuel Lockhart ¹, Suzanne Craft ¹
¹Wake Forest School of Medicine, Department of Internal Medicine - Gerontology - Winston-Salem (United States), ²Wake Forest School of Medicine, Department of Internal Medicine - Gerontology - Winston-Salem (United States) - Winston-Salem (United States), ³Wake Forest School of Medicine, Department of Biostatistics and Data Science - Winston-Salem (United States)
- P128 The Pre-Clinical Alzheimer's Cognitive Composite Score: Informing Clinical Meaningfulness through the Alzheimer's Disease Continuum**
James David Doecker ¹, Marcela Cespedes ¹, Timothy Cox ², Rosita Shishegar ³, Christopher James Fowler ⁴, Stephanie Rainey-Smith ^{5,6,7,8}, Hamid Sohrabi ^{9,10}, Shaun Markovic ^{9,10}, Jurgan Fripp ¹, Cai Gillis ¹¹, Nancy Maserejian ¹¹, Yen Ying Lim ¹², Jason Hassenstab ^{13,14}, Paul Maruff ¹⁵
¹Australian E-Health Research Centre, CSIRO - Herston (Australia), ²Australian E-Health Research Centre, CSIRO - Canberra (Australia), ³Australian E-Health Research Centre, CSIRO - Parkville (Australia), ⁴The University of Melbourne, The Florey Institute - Parkville (Australia), ⁵Centre for Healthy Ageing, Murdoch University - Murdoch (Australia), ⁶Australian Alzheimer's Research Foundation - Perth (Australia), ⁷University of Western Australia - Perth (Australia), ⁸Edith Cowan University, School of Medical and Health Sciences, Centre of Excellence for Alzheimer's Disease Research & Care - Joondalup (Australia), ⁹Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Murdoch (Australia), ¹⁰Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute - Nedlands (Australia), ¹¹Biogen - Boston (United States), ¹²Turner Institute for Brain and Mental Health, School of Psychological Sciences - Monash (Australia), ¹³Knight Alzheimer Disease Research Center, Washington University School of Medicine - St Louis (United States), ¹⁴Department of Neurology, Washington University School of Medicine - St. Louis (United States), ¹⁵Cogstate - Melbourne (Australia)
- P129 Automated linguistic metrics from a novel, remote, smartphone-based self-assessment of cued narration and free recall correlate with brain atrophy in language and memory networks in early Alzheimer's disease**
Irma T. Kurniawan ¹, Michal K. Kosek ², Raphael M. Ullmann ¹, Arnaud M. Wolfer ¹, Stefan Holiga ¹, Eduardo A. Aponte ¹, Thanneer M. Perumal ¹, Kirsten I. Taylor ¹
¹Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. - Basel (Switzerland), ²Roche Global IT Solution Centre, Warsaw, Poland - Warsaw (Poland)
-  **P130 Characterising progressive decline across multiple cognitive domains in preclinical Alzheimer's disease**
 Rosita Shishegar ¹, Timothy Cox ², Hamid R. Sohrabi ³, Shaun Markovic ³, Jurgan Fripp ⁴, Vincent Doré ¹, Pierrick Bourgeat ⁴, Jason Hassenstab ⁵, Yen Ying Lim ⁶, Paul Maruff ⁷, Colin L. Masters ⁸, James D Doecker ⁸
¹Australian E-Health Research Centre, CSIRO - Melbourne (Australia), ²Australian E-Health Research Centre, CSIRO - Canberra (Australia), ³Centre for Healthy Ageing, Murdoch University - Murdoch (Australia), ⁴Australian E-Health Research Centre, CSIRO - Brisbane (Australia), ⁵Department of Psychological and Brain Sciences, Washington University in Saint Louis - Saint Louis (United States), ⁶Turner Institute of Brain and Mental Health, School of Psychological Sciences, Monash University - Clayton (Australia), ⁷Cogstate Ltd. - Melbourne (Australia), ⁸The University of Melbourne, The Florey Institute - Melbourne (Australia)
- P131 Do Alzheimer's Risk Genes Also Predict Cognitive Decline?**
Shane Fernandez ^{1,2}, Rosita Shishegar ³, Paul Maruff ^{4,5}, Colin Masters ⁴, Victor Villemagne ^{6,7}, Timothy Cox ³, Vincent Doré ^{3,7}, Tenielle Porter ^{1,2}, Simon Laws ^{1,2}
¹Centre for Precision Health, Edith Cowan University - Perth (Australia), ²Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University - Perth (Australia), ³Australian E-Health Research Centre, CSIRO - Melbourne (Australia), ⁴Florey Institute of Neuroscience and Mental Health, The University of Melbourne - Melbourne (Australia), ⁵Cogstate Ltd - Melbourne (Australia), ⁶Department of Psychiatry, University of Pittsburgh, - Pittsburgh (United States), ⁷Department of Molecular Imaging and Therapy and Centre for PET, Austin Health, - Melbourne (Australia)
- P132 Forecasting Future Dementia Risk Using a Digital Clock Drawing Assessment in an African American Population**
Jeff Pobst ¹, Sean Tobyne ¹, Ali Jannati ^{1,2}, Russell Banks ^{1,3}, David Libon ^{1,4}, Rodney Swenson ^{1,5}, Melissa Lamar ^{6,7}, Lisa Barnes ^{6,7,8}, David Bates ¹, John Showalter ¹, Alvaro Pascual-Leone ^{1,2,9}
¹Linus Health, Inc. - Boston, Massachusetts (United States), ²Department of Neurology, Harvard Medical School - Cambridge, Massachusetts (United States), ³Michigan State University - East Lansing, Michigan (United States), ⁴Rowan University - Stratford, New Jersey (United States), ⁵University of North Dakota School of Medicine and Health Sciences - Fargo, North Dakota (United States), ⁶Rush Alzheimer's Disease Center - Chicago, Illinois (United States), ⁷Department of Psychiatry and Behavioral Sciences, Rush University Medical Center - Chicago, Illinois (United States), ⁸Department of Neurological Sciences, Rush University Medical Center - Chicago, Illinois (United States), ⁹Hinda and Arthur Marcus Institute for Aging Research, Deanna and Sidney Wolk Center of Memory Health, Hebrew Senior Life - Boston, Massachusetts (United States)
- P133 Bridging the Assessment Gap: Newly Developed Neuropsychiatric Cognitive Assessments on the Cognivue® Platform Show Strong Correlation with Traditional Gold Standard Tests**
James Galvin ¹
¹University of Miami Comprehensive Center for Brain Health - Miami (United States)
- P134 Efficient and Automated Cognitive Pre-Screening for Clinical Trials using the Montreal Cognitive Assessment (MoCA) XpressO Tool and Automated Report**
 Sivan Klil-Drori ¹, Katie Bodenstien ², Lara Kojok ², Shuo Mila Sun ³, Youssef Ghantous ², **Ziad Nasreddine** ²
¹McGill University - Montreal, Qc (Canada), ²MoCA Cognition Clinic and Institute - Montreal, Qc (Canada), ³Harvard University - Cambridge, Ma (United States)

POSTER PRESENTATIONS

- P135 **Attaching clinical meaningfulness to CDR-SB score**
Danielle Digregorio¹
¹WCG - Princeton (United States)
- P136 **Analysis of Aβ(1-42) Oligomers by Cyclic Ion Mobility SPECTROMETRY in spiked HUMAN cerebrospinal fluid**
Mikuláš Vlk¹, John Hey², Walter Korfmacher², Alexander Muck³, Martin Hubálek¹, Josef Cvačka¹
¹Institute of Organic Chemistry and Biochemistry of the CAS, Mass Spectrometry Group - Prague (Czech Republic), ²Alzheon - Framingham (United States), ³Waters Corporation, Analytical Professional Services EMEA - Wilmslow (United Kingdom)
- P137 **Sex Differences in Predicting Progression in Cognitively Unimpaired ADNI Participants Using Cognitive Test Performance**
Adam Diaz^{1,2}, Melanie J. Miller^{1,2}, Marta Mila Aloma^{1,3}, Zack Hausle^{1,3}, Pamela Zobel-Thropp^{1,3}, Duygu Tosun³, Rachel Nosheny⁴, Leslie M. Shaw⁵, Michael W. Weiner^{1,2}
¹Northern California Institute for Research and Education (NCIRE) - San Francisco (United States), ²Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases - San Francisco (United States), ³University of California, San Francisco, Department of Radiology and Biomedical Imaging - San Francisco (United States), ⁴University of California, San Francisco, Department of Psychiatry and Behavioral Sciences - San Francisco (United States), ⁵University of Pennsylvania, Perelman School of Medicine - Pennsylvania (United States)

THEME: Behavioral disorders and clinical trials

- P138 **Effects of brexpiprazole on agitation associated with dementia due to Alzheimer's disease: analysis of pooled efficacy data from two Phase 3 fixed-dose trials by baseline agitation frequency**
Jyoti Aggarwal¹, Daniel Lee¹, Nanco Hefting², Dalei Chen¹, Denise Chang¹, Zhen Zhang¹, Maia Miguelez¹, Saloni Behl¹
¹Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), ²H. Lundbeck A/S - Valby, Copenhagen (Denmark)
- P139 **Effects of brexpiprazole on agitation associated with dementia due to Alzheimer's disease: analysis of pooled response data from two Phase 3 fixed-dose trials**
Daniel Lee¹, Jyoti Aggarwal¹, Nanco Hefting², Dalei Chen¹, Denise Chang¹, Saloni Behl¹
¹Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), ²H. Lundbeck A/S - Valby, Copenhagen (Denmark)
- P140 **Design of ADEPT-2, a phase 3, parallel group study to evaluate KarXT (xanomeline-trospium) as a treatment for psychosis associated with Alzheimer's disease**
Minsu Kang¹, Carolyn Watson¹, Jeffrey Cummings², George Grossberg³, Ronald Marcus¹, Paul Yeung¹
¹Karuna Therapeutics - Boston (United States), ²Chambers-Grundy Center for Transformative Neuroscience, University of Nevada, Las Vegas - Las Vegas (United States), ³Department of Psychiatry & Behavioral Neuroscience, Saint Louis University School of Medicine - Saint Louis (United States)


THEME: Health economics and clinical trials

- P141 **Implications of Treatment Duration and Intensity on the Value of Alzheimer's Treatments**
Soeren Mattke¹, Tabasa Ozawa¹, Mark Hanson¹
¹USC - Los Angeles (United States)
- P142 **Efficacy of pharmacological treatments of agitation and aggression in patients with dementia: A Systematic Review and Network Meta-Analysis**
Ismaeel Yunusa¹
¹University of South Carolina College of Pharmacy - Columbia (United States)
-  P143 **Assessing health system capacity for delivery of a disease-modifying therapy for Alzheimer's disease: a multi-country analysis**
Ilke Mirik Danaci¹, Valerie Crowell¹, Nathalie Budd², Haakon B Nygaard³
¹F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²F. Hoffmann-La Roche Ltd - Mississauga (Canada), ³Division of Neurology and Djavad Mowafaghian Centre for Brain Health - Vancouver (Canada)

THEME: Epidemiology and clinical trials

- P144 **State Department of Motor Vehicles clinician reporting mandates of dementia diagnoses: Evidence for risks and benefits**
Hankyung Jun¹, Ying Liu², Emily Chen², Andrew Becker², Soeren Mattke²
¹Harvard Medical School - Boston (United States), ²University of Southern California - Los Angeles (United States)
- P145 **Age-specific relative comorbidity burden of mild cognitive impairment: A US database study**
Gang Li¹, Nicola Toschi², Viswanath Devanarayan¹, Richard Batrla¹, Tommaso Boccatto², Min Cho¹, Matteo Ferrante², Feride Frech¹, James Galvin³, David Henley⁴, Soeren Mattke⁵, Susan De Santi¹, Harald Hampel¹
¹Eisai Inc - Nutley (United States), ²University of Rome Tor Vergata - Rome (Italy), ³University of Miami - Miami (United States), ⁴Janssen Research & Development - New Brunswick (United States), ⁵University of Southern California - Los Angeles (United States)
- P146 **Comorbidities Occurring Before and After Diagnosis of Mild Cognitive Impairment or Alzheimer's Disease: A Large US Nationwide Electronic Health Record Cohort Study**
Lisa Vinikoor-Imler¹, Olga Sanchez-Solino¹, Emma Xiaomeng Yue¹, Isabella Boroje¹
¹AbbVie Inc. - Chicago (United States)



- P147 **Biomarker and clinical correlations for amyloid targeting monoclonal antibody (mAb) treatment responses**
Jonathan Wagg¹, Nicolas Fournier¹, Garance Lucken¹, Clarisse Schumer², Olivier Sol¹, Julian Gray¹, Marija Vukicevic¹, Marie Kosco-Vilbois¹, Andrea Pfeifer¹, Johannes Streffer¹
¹AC Immune SA - Lausanne (Switzerland), ²EPFL - Lausanne (Switzerland)
- P148 **High prevalence of amyloid cerebral pathology in older adults with cognitive frailty - an indication for anti-amyloid therapies?**
Sandrine Sourdet¹, Gaëlle Soriano¹, Bruno Vellas¹
¹Gerontopôle - Toulouse (France)
-  P149 **Acculturation-related characteristics associated with research attitudes among underrepresented populations recruited to an Alzheimer's disease preclinical trial**
Christian Salazar¹, Hye-Won Shin¹, Melanie Tallakson¹, Edwin Duran¹, Russ Eunji¹, Maria Corona¹, Romina Romero¹
¹UC Irvine Institute for Memory Impairments and Neurological Disorders - Irvine (United States)
- P150 **Sildenafil is a candidate drug for Alzheimer's disease: Real-world patient data observation**
Cheng Feixiong¹, Zhang Pengyue², Jeffrey Cummings³
¹Cleveland Clinic - Cleveland (United States), ²Indiana University - Bloomington (United States), ³University of Nevada Las Vegas - Las Vegas (United States)

THEME: Animal model

- P151 **Deciphering the mechanisms of action of cognitive gain using the multidomain lifestyle intervention protocol – from human RCTs to mice**
Vilma Alanko^{1,2}, Francesca Eroli², Alina Solomon^{3,4}, Krister Häkansson¹, Tiia Ngandu⁵, Tobias Hartmann^{6,7}, Per Nilsson², Miia Kivipelto^{1,4,8}, Silvia Maioli², Anna Matton^{1,2,4}
¹Division of Clinical Geriatrics, Department of NVS, Karolinska Institutet - Solna (Sweden), ²Division of Neurogeriatrics, Department of NVS, Karolinska Institutet - Solna (Sweden), ³Institute of Clinical Medicine/Neurology, University of Eastern Finland - Kuopio (Finland), ⁴Ageing Epidemiology (AGE) Research Unit, Imperial College London - London (United Kingdom), ⁵Population Health Unit, Finnish Institute for Health and Welfare - Helsinki (Finland), ⁶Deutsches Institut für Demenz Prävention (DIDP), Saarland University - Homburg (Germany), ⁷Department of Experimental Neurology, Medical Faculty, Saarland University - Homburg (Germany), ⁸Theme Inflammation and Aging, Karolinska University Hospital - Solna (Sweden)
- P152 **Subcellular and secretory effects of the App^{ML-F} knock-in in mice neurons**
Sophia Schediin-Weiss¹, Yang Yu¹, Robin Z. Zhou¹, Lars O. Tjernberg¹
¹Karolinska Institutet - Solna (Sweden)

THEME: New therapies and clinical trials

-  P153 **Impact of adherence on cognitive outcomes in a pilot study of the Cogstim model**
Raymond L Ownby¹
¹Nova Southeastern University - Fort Lauderdale (United States)
- P154 **Pivotal trial of low-intensity pulsed ultrasound therapy for early stage of Alzheimer's disease (LIPUS-AD) –Rationale and design-**
Hiroaki Shimokawa^{1,2}, Masanori Akishita³, Masafumi Ihara⁴, Satoshi Teramukai⁵, Aiko Ishiki⁶, Yoji Nagai⁷, Hajimu Kato², Masanori Fukushima⁸
¹International University of Health and Welfare - Narita (Japan), ²Sound Wave Innovation Inc. - Tokyo (Japan), ³University of Tokyo - Tokyo (Japan), ⁴National Cerebrovascular and Cardiovascular Center - Suita (Japan), ⁵National Cerebrovascular and Cardiovascular Center - Kyoto (Japan), ⁶Tohoku Medical and Pharmaceutical University - Sendai (Japan), ⁷Kyoto University - Kyoto (Japan), ⁸Learning Health Society Institute - Nagoya (Japan)
- P155 **Masupirdine (A Pure 5-HT6 Receptor Antagonist) for the Treatment of Agitation in Patients with Dementia of Alzheimer's Type - Rationale and Phase-3 Study Design**
Ramakrishna Nirogi¹, Jyothsna Ravula¹, Satish Jetta¹, Vinod Kumar Goyal¹, Pradeep Jayarajan¹, Vijay Benade¹, Anil Shinde¹, Santosh Kumar Pandey¹, Ramkumar Subramanian¹, Abdul Rasheed Mohammed¹, Venkat Jasti¹
¹Suven Life Sciences Ltd - Hyderabad (India)
- P157 **Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH): a phase 2a proof-of-concept trial of a novel anti-neuroinflammatory small molecule drug candidate**
Linda Van Eldik¹, Wendy Ziai², Lauren Sansing³, Daniel Hanley²
¹University of Kentucky - Lexington (United States), ²Johns Hopkins University - Baltimore (United States), ³Yale University - New Haven (United States)
- P158 **Treatment of early symptomatic Alzheimer's disease with nasal Protollin to activate monocytes and clear amyloid beta**
Panayota Kolypetri¹, Patrick Da Silva¹, Lei Liu¹, Christian D. Gauthier¹, Taylor J. Saraceno¹, Tarun Singhal¹, Seth A. Gale¹, Tanuja Chitnis¹, Dennis J. Selkoe¹, Howard L. Weiner¹
¹Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School - Boston (United States)

POSTER PRESENTATIONS

THEME: Proof of concept/Translational research for Alzheimer Drug Development interventions

- P159 **D-peptide-magnetic nanoparticles disaggregate tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease**
Ke Hou¹, Hope Pan¹, David Eisenberg¹
¹UCLA - Los Angeles (United States)
- P160 **Structural dynamics of amyloid- β protofibrils and action of lecanemab as observed by high-speed atomic force microscopy**
Kenjiro Ono¹, Takahiro Nakayama², Mayumi Tsuji³, Kenichi Umeda², Tatsunori Oguchi³, Hiroki Konno², Moeko Shinohara¹, Yuji Kiuchi³, Noriyuki Kodera², David B. Teplow⁴
¹Kanazawa University Graduate School of Medical Sciences - Kanazawa (Japan), ²Nano Life Science Institute, Kanazawa University - Kanazawa (Japan), ³Showa University School of Medicine - Tokyo (Japan), ⁴David Geffen School of Medicine at UCLA - Los Angeles (United States)
- P161 **APOE-Targeted Epigenome Therapy for Alzheimer's Disease: Pre-Clinical Studies**
Ornit Chiba-Falek^{1,2}, Boris Kantor^{1,2}
¹Duke University - Durham (United States), ²CLAIRIgene, LLC - Durham (United States)
-  P162 **A Possible Pathogenic PSEN2 Gly56Ser Mutation in a Korean Patient with Early-Onset Alzheimer's Disease**
Da-Eun Jeong¹, Min Ju Kang¹
¹Department of Neurology, Veterans Health Service Medical Center - Seoul (Korea, Republic of)
- P163 **Effect of spectral binning in x-ray scattering method for non-invasively characterizing amyloids**
Eshan Dahal¹, Sabri Amer¹, Karthika Suresh¹, Olivia Sandvold², Peter Noël², Aldo Badano¹
¹U.S. Food and Drug Administration - Silver Spring (United States), ²University of Pennsylvania - Philadelphia (United States)
- P164
- P165 **Equilibrative nucleoside transporter 1 (ENT1) as a promising therapeutic target to rescue pathological features and alleviate cognitive impairment in Alzheimer's disease**
Chien-Yu Lin^{1,2}, Ching-Pang Chang^{1,2}, Kuo-Chen Wu^{2,3}, Ching-Wen Wu^{1,2}, Chun-Jung Lin^{2,3}, Yijuang Chern^{1,2}
¹Institute of Biomedical Sciences, Academia Sinica - Taipei (Taiwan, Republic of China), ²Biomedical Translation Research Center, Academia Sinica - Taipei (Taiwan, Republic of China), ³School of Pharmacy, National Taiwan University - Taipei (Taiwan, Republic of China)
- P166 **Study of novel copper and zinc binding analogue of GMP-1 in Tg4510 tauopathy mouse model**
Bengt Winblad¹, Zhe Zhao¹, Pavel Pavlov¹
¹Karolinska Institutet - Solna (Sweden)
- P167 **Novel small molecule poly-disaggregator therapeutics for AD, ALS and FTD reduce TDP-43 oligomerization, aggregation, and pathology**
Marcela Kokes¹, Vidhu Mathur¹, Eric Shao¹, Shruti Arya¹, Catherine Planey¹
¹Acelot - Palo Alto (United States)
- P168 **Differences in Glutaminyl Cyclase protein levels in Mild Cognitive Impairment subjects**
Xavier Morato¹, Amanda Cano¹, Sergi Valero¹, Raul Nuñez¹, Raquel Puerta¹, Jose Antonio Allué¹, Leticia Sarasa¹, Agustín Ruiz¹, Mercè Boada¹
¹FUNDACIO ACE - Barcelona (Spain)
- P169 **White matter hyperintensity accumulation is related to cerebral amyloid angiopathy and neurodegeneration in autosomal dominant and sporadic AD**
Zahra Shirzadi¹, Stephanie Schultz¹, Wai-Ying Yau¹, Nelly Friedrichsen², Kejal Kantarci³, Gregory Preboske³, Clifford Jack Jr³, Brian Gordon², Eric Mcdade², Tammie Benzinger², Randall Bateman², Steven Greenberg¹, Reisa Sperling¹, Aaron Schultz¹, Jasmeer Chhatwal¹
¹Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ²Washington University in St. Louis School of Medicine - St. Louis (United States), ³Mayo Clinic, Radiology - Rochester (United States)
- P170 **Systematic in silico analysis of clinically tested drugs for reducing amyloid beta plaque accumulation in Alzheimer's disease**
Sarah Head¹, Raibatak Das¹, Brian Campbell², Dan Zweifel², John Burke¹, Joshua Apgar¹, Fei Hua¹
¹Applied BioMath - Concord, Massachusetts (United States), ²Prothena Biosciences Inc. - South San Francisco, California (United States)
- P171 **In Silico Simulation of Dementia-Alzheimer-Syndrome: Application of hybrid computing approach to the study of emergent behavior**
Ara Khachaturian¹, Zaven Khachaturian¹, Jeanmarie Bouteiller², Eva Troppová³, Vaclav Snášel⁴, Vit Vondrák⁴, Jiri Damborský⁵, Stanislav Mazurenko⁵, Josef Šivic³, Vit Dočkal³
¹Campaign to Prevent Alzheimer's Disease - Rockville (United States), ²University of Southern California - Los Angeles (United States), ³Czech Institute of Informatics, Robotics and Cybernetics, Czech Technical University - Prague (Czech Republic), ⁴Technical University of Ostrava - Ostrava (Czech Republic), ⁵International Clinical Research Center of St. Anne's University Hospital - Brno (Czech Republic)
- P172 **Neuroprotective and mnemonic-improving effects of Fluoroethylnormemantine (FENM) in the AB25-35 mouse model of Alzheimer's disease**
Allison Carles¹, Aline Freysson², Florent Perin-Dureau², Gilles Rubinstenn², Tangui Maurice¹
¹MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France - Montpellier (France), ²ReST Therapeutics, Montpellier, France - Paris (France)



- P173 Nanolithium has a dual potential in Alzheimer's disease: to treat Neuropsychiatric Symptoms and modify disease course**
 Maria Eugenia Soto-Martin ¹, Solene Guilliot ², Pierre-Jean Ousset ¹, Karim Bennys ³, Claire Paquet ⁴, Jacques Touchon ⁵, Edward N Wilson ⁶
¹Alzheimer's disease Memory Research & Clinical center, Department of Geriatrics, Gerontopole, Hôpital Lagrave - Toulouse (France), ²Medesis Pharma - Baillargues (France),
³Alzheimer's disease Memory Research & Clinical center, Department of Neurology, University Hospital Gui de Chauliac - Montpellier (France), ⁴Cognitive Neurology Center,
 Lariboisière Fernand-Widal Hospital APHP Université de Paris Cité - Paris (France), ⁵University of Montpellier - Montpellier (France), ⁶Neurology & Neurological Sciences,
 Stanford School of Medicine - Stanford (United States)
- P174 Advancing Diverse Recruitment by Assessing Facilitators and Barriers to Participation in Alzheimer's and Dementia-Related Research**
 John Lucas ¹, Shawna Green ¹, Maisha Robinson ¹, Aaron Spaulding ¹
¹Mayo Clinic - Jacksonville (United States)
- P175 Fosgonimeton, a small-molecule positive modulator of the HGF/MET system, attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease**
 Sherif Reda ¹, Sharay Setti ¹, Andrée-Anne Berthiaume ¹, Wei Wu ¹, Jewel Johnston ¹, Robert Taylor ¹, Kevin Church ¹
¹Athira Pharma, Inc. - Bothell (United States)
- P176 A recombinant molecular chaperone domain active against Alzheimer pathology can transport proteins over the blood brain barrier and into neurons**
 Jan Johansson ¹
¹Karolinska Institutet - Huddinge (Sweden)
- P177 Unraveling the therapeutic potential of novel hyaluronic acid estradiol conjugate ND108E in Alzheimer's Disease: Mechanistic insights and future directions**
 Chia-Lung Hou ¹, Szu-Yuan (viola) Lee ¹, Jia-Chi Wang ¹, Ting-An Chen ¹, Kai-Ting Chang ¹, Mu-Hsuan Chen ², Hsiao-Chun Lin ², Tzu Chao ², Tsy-Jiuan Wang ³, Jeng-Rung Chen ²
¹Holy Stone HealthCare - Taipei (Taiwan, Republic of China), ²National Chung-Hsing University - Taichung (Taiwan, Republic of China), ³National Taichung University of Science and Technology - Taichung (Taiwan, Republic of China)
- P178 Structural and biochemical similarities of protofibrils and plaque fibrils: implications for anti-amyloid immunotherapy**
 Andrew Stern ¹, Yang Yang ², Shanxue Jin ¹, Keitaro Yamashita ², Angela Meunier ¹, Wen Liu ¹, Yuqi Cai ¹, Maria Ericsson ³, Lei Liu ¹, Michel Goedert ², Sjors Scheres ², Dennis Selkoe ¹
¹Ann Romney Center For Neurologic Diseases, Brigham And Women's Hospital, Harvard Medical School - Boston (United States), ²MRC Laboratory for Molecular Biology - Cambridge (United Kingdom), ³Harvard Medical School - Boston (United States)

THEME: Digital health/E-trials

- P179 Development of a mild cognitive impairment risk prediction model using electronic health record data**
 Gang Li ¹, Viswanath Devanarayan ¹, Rachel Halpern ², Richard Batrla ¹, Susan De Santi ¹, Feride Frech ¹, Jo Vandercappellen ¹, Ara S. Khachaturian ³, Richard Crislip ⁴, Soeren Matkce ⁵, Harald Hampel ¹
¹Eisai - Nutley (United States), ²Optum - Eden Prairie (United States), ³Prevent Alzheimer's Disease 2020, Inc. - Rockville (United States), ⁴OptumCare - Phoenix (United States), ⁵University of Southern California - Los Angeles (United States)
- P180 Validating a novel digital cognitive platform: sensitivity to change following an alcohol challenge**
 John Dyer ¹, Florentine Barbey ², Md Nurul Islam ², Judith Jaeger ^{3,4}, Brian Murphy ², Niamh Kennedy ⁵
¹Cumulus Neuroscience - Belfast (United Kingdom), ²Cumulus Neuroscience - Dublin (Ireland), ³CognitionMetrics - Stamford, Ct (United States), ⁴Albert Einstein College of Medicine - Bronx, Ny (United States), ⁵University of Ulster - Coleraine (United Kingdom)
- P181 The effects of home-based, semi-computerized cognitive training on cognitive function in community dwelling older adults**
 Geon Ha Kim ¹, Bori R. Kim ², Haeun Kim ³, Jee Hyang Jeong ⁴
¹Department of Neurology, Ewha Womans University, College of Medicine - Seoul (Korea, Republic of), ²Ewha Medical Research, Institute Ewha Womans University - Seoul (Korea, Republic of), ³Department of Artificial Intelligence Convergence, Ewha Womans University - Seoul (Korea, Republic of), ⁴Ewha Womans University - Seoul (Korea, Republic of)
-  **P182 Comparing the Effects of Combined Cognitive and Functional Skills Training to Skills Training Alone: Burst Training Increases Training Gains without Increasing Drop-outs**
 Philip Harvey ¹, Peter Kallestrup ², Sara Czaja ³
¹University of Miami Miller School of Medicine - Miami (United States), ²i-Function - Miami (United States), ³Weill Cornell Medical Center - New York (United States)
- P183 A real-world, longitudinal observational study in patients with Alzheimer's Disease dementia and healthy controls, using frequent repeated digital measurements performed at-home on the Cumulus Platform: a preliminary report**
 Alison Buick ¹, Azar Alexander-Sefre ¹, Shannon Diggin ¹, John Dyer ¹, Brian Murphy ², Hugh Nolan ², Laura Rueda-Delgado ², James Rowe ³, Kinan Muhammed ⁴
¹Cumulus Neuroscience Ltd - Belfast (United Kingdom), ²Cumulus Neuroscience Ltd - Dublin (United Kingdom), ³Department of Clinical Neurosciences, University of Cambridge - Cambridge (United Kingdom), ⁴Nuffield Department of Clinical Neurosciences, University of Oxford - Oxford (United Kingdom)
- P184 Enhancing Automated Transcription for Speech-Based Screening in Alzheimer's Disease**
 Udeepa Meepegama ¹, Caroline Skirrow ¹, Michael Ropacki ², Emil Fristed ¹, Jack Weston ¹
¹Novoic - London (United Kingdom), ²Strategic Global Research & Development - Temecula (United States)

POSTER PRESENTATIONS

- P185** **A Hybrid Deep Learning Audio-Visual Approach for Mild Cognitive Impairment Prediction: I-CONNECT Study**
Farida Far Poor¹, Muath Alsuhaibani¹, Mohammad H Mahoor¹, Liu Chen², [Hiroko H Dodge](#)²
¹Department of Electrical and Computer Engineering, University of Denver - Denver (United States), ²Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)
- P186** **Feasibility of the Cumulus electrophysiological neurocognitive platform to enable de-centralised trials in Alzheimer's Disease**
Florentine Marie Barbey¹, Christopher J Barnum², [Alison R Buick](#)³, John Frederick Dyer³, Md Nurul Islam¹, Jack Fogarty⁴, Hugh Nolan¹, Brian Murphy¹
¹Cumulus Neuroscience Ltd. - Dublin (Ireland), ²INmune Bio Inc. - Boca Raton (United States), ³Cumulus Neuroscience Ltd. - Belfast (United Kingdom), ⁴Nanyang Technological University - Singapore (Singapore)
- P187** **Accelerating Sustainable Adoption and Justification of Digital Clinical Detection Applications for Cognitive Impairment and Dementia into Established Healthcare Systems**
[Ara Khachaturian](#)¹, Brittany Cassin², Glen Finney³, Phyllis Barkman Ferrell⁴, Eric Klein⁴, Malaz Boustani⁵, Zaven Khachaturian¹
¹Campaign to Prevent Alzheimer's disease - Rockville (United States), ²DigiCARE Realized Inc. - Old Bridge (United States), ³Geisinger Health - Danville (United States), ⁴Eli Lilly and Company - Indianapolis (United States), ⁵Indiana University - Indianapolis (United States)
- P188**
- P189** **Correlation between Altimida's digital cognitive assessment and standard neuropsychological tests in individuals with mild cognitive impairment and cognitively healthy volunteers**
[Emmanuel Streef](#)¹, Adria Tort Merino², Alberto Ferrari³, Gonzalo Sanchez-Benavides^{4,5,6,7}, Carolina Minguillon^{4,5}, Silvia Fallone Fallone⁸, Robbert Harms⁹, Ioannis Tarnanas¹⁰, Mircea Balasa², M. Florencia Lulita¹¹
¹Altimida Inc. - Washington (United States), ²Hospital Clinic, IDIBAPS - Barcelona (Spain), ³Altimida Inc. - Rome (Italy), ⁴BarcelonaMeta Brain Research Center (BBRC) - Barcelona (Spain), ⁵Pasqual Maragall Foundation - Barcelona (Spain), ⁶Hospital del Mar Medical Research Institute - Barcelona (Spain), ⁷(CIBERFES), Instituto de Salud Carlos III - Madrid (Spain), ⁸Altimida Inc. - Maastricht (Netherlands), ⁹Altimida Inc. - Nijmegen (Netherlands), ¹⁰Altimida Inc. - Thessaloniki (Greece), ¹¹Altimida Inc. - Barcelona (Spain)
- P190** **Building an Evidence Catalog of Digital Measurement Technologies to Accelerate Endpoint Development in Alzheimer's Disease and Related Dementias Clinical Trials**
Sarah Averill Lott¹, Emmanuel Streef², Piper Fromy³, Jennifer Goldsack⁴, On Behalf of The Dime Core Digital Measures Of ADRD Project Team⁴
¹The Digital Medicine Society - Johnstown (United States), ²Altimida - Washington, DC (United States), ³The Digital Medicine Society - Saumur (France), ⁴The Digital Medicine Society - Boston (United States)
- P191** **Advancing Computerized Cognitive Assessment: Cognivue's® Enhanced Normative Range Data Sets the New Gold Standard for Sensitivity and Patient Profiling**
[James Galvin](#)¹
¹University of Miami Comprehensive Center for Brain Health - Boca Raton (United States)
- P192** **The Brain Health Champion Study: A Health Coaching Intervention with Mobile Technology in Older Adults with Mild Cognitive Impairment or Risk Factors for Dementia- An Update**
[Kayla Riera](#)¹, Ashley Park¹, Brittany Mcfeeley¹, Demsina Babazadeh¹, Abby Altman¹, Kirk Daffner¹, Seth Gale¹
¹Brigham and Women's Hospital - Boston (United States)

THEME: Beyond Amyloid and Tau

-  **P193** **Angiogenic Mechanisms in Alzheimer's Disease: A Systematic Review of Neuropathological Evidence**
[Arunima Kapoor](#)¹, Daniel Nation¹
¹University of California, Irvine - Irvine (United States)
- P194** **Do Mouse Data Lie? For Buntanetap They Totally Predict Human Outcomes All the Way to Clinical Efficacy**
[Maria Maccacchini](#)¹, Cheng Fang¹
¹Annovis Bio - Berwyn (United States)
- P195** **Fluid Biomarker Results from an Open-Label Pilot Study of Senolytic Therapy for Alzheimer's Disease, STOMP-AD**
[Miranda E. Orr](#)^{1,2,3}, Valentina R Garbarino^{4,5}, Juan Pablo Palavicini⁴, Tiffany F. Kautz^{4,5}, Shiva K Dehkordi^{6,5}, Habil Zare^{6,5}, Peng Xu^{7,8}, Bin Zhang^{7,8}, Justin Melendez^{9,10}, Nicolas Barthelemy^{9,10}, Randall J Bateman^{9,10}, Mitzi M Gonzales^{11,5}
¹Wake Forest University School of Medicine, Gerontology and Geriatric Medicine, - Winston-Salem (United States), ²Wake Forest Alzheimer's Disease Research Center - Winston-Salem (United States), ³Salisbury VA Medical Center - Salisbury (United States), ⁴University of Texas Health Science Center at San Antonio, Department of Medicine, - San Antonio (United States), ⁵Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases - San Antonio (United States), ⁶University of Texas Health Science Center at San Antonio Department of Cell Systems and Anatomy, - San Antonio (United States), ⁷Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, - New York (United States), ⁸Mount Sinai Center for Transformative Disease Modeling - New York (United States), ⁹Washington University School of Medicine, Department of Neurology - St Louis (United States) - St Louis (United States), ¹⁰The Tracy Family SILQ Center - St Louis (United States), ¹¹University of Texas Health Science Center at San Antonio, Department of Neurology - San Antonio (United States)



- P196 Plasma and cerebrospinal fluid proteomic association during Alzheimer's disease (AD) progression suggests possible new targets for treating AD patients**
Ying Wang¹, Ricardo Gonzalo², Carla Minguet², Ana Maria Ortiz², Scott Lohr¹, Mercè Boada³, Oscar López⁴, Antonio Paez², Jorge Loscos⁵, Jesús Canudas⁵, María Pascual⁵, Jose Terencio², Montserrat Costa², Chunmiao (mia) Feng¹, Benoit Lehallier¹
¹Alkagest, a Grifols company - San Carlos (United States), ²Grifols - Barcelona (Spain), ³Universitat Internacional de Catalunya - Barcelona (Spain), ⁴University of Pittsburgh - Pittsburgh (United States), ⁵Araclon, a Grifols company - Zaragoza (Spain)
- P197 Whole transcriptomic cell free messenger RNA characterization of Alzheimer's disease in cerebrospinal fluid compared to plasma from human subjects**
 Rhys De Sota¹, Robert Rissman², James Brewer², Samantha Khoury¹, Shusuke Toden¹, John Sninsky¹
¹Molecular Stethoscope - South San Francisco (United States), ²University of California, San Diego - San Diego (United States)
- P198 CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease**
Charlotte Teunissen¹, Emma L. Van Der Ende², Sjors In 't Veld², Iris Hanskamp², Sven Van Der Lee^{3,4}, Janna Dijkstra⁵, John C. Van Swieten⁶, David J. Irwin⁷, Alice Chen-Plotkin⁷, William T. Hu⁸, Afina Lemstra⁹, Yolande A.L. Pijnenburg⁹, Wiesje M. Van Der Flier^{9,10}, Marta Del Campo^{9,11}, Lisa Vermunt^{2,9}
¹Amsterdam UMC - Amsterdam (Netherlands), ²Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ³Alzheimer Center Amsterdam, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ⁴Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Pays-Bas) - Amsterdam (Netherlands), ⁵Genomics of Neurodegenerative Diseases and Aging, Human Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ⁶Alzheimer Center and Department of Neurology, Erasmus University Medical Center - Rotterdam (Netherlands), ⁷Department of Neurology, Perelman School of Medicine, University of Pennsylvania - Philadelphia (United States), ⁸Department of Neurology, Emory University School of Medicine - Atlanta (United States), ⁹Alzheimer Center Amsterdam, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ¹⁰Department of Epidemiology and Data Science, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ¹¹Barcelonabeta Brain Research Center (BBRC) - Barcelona (Spain)
- P199 Lipid Dicarbonyl Scavengers for the Prevention of Alzheimer's Disease**
John A. Rathmacher¹, Naji N. Abumrad², Paul A. Newhouse²
¹MTI BioTech Inc - Ames (United States), ²Vanderbilt University Medical Center - Nashville (United States)
- P200 Translation Studies and Clinical Development of THN391, a Novel Anti-Fibrin Antibody for the Treatment of Dementia**
Jeffrey Stavenhagen¹, Mathias Rickert¹, Kenneth Flanagan¹, Hank Cheng¹, Anjana Supphahia¹, Vasudha Salgotra¹, Jae Kyu Ryu², Katerina Akassoglou²
¹Therini Bio - San Francisco (United States), ²Gladstone Institute - San Francisco (United States)
- P201 Gamma-Induction in FrontoTemporal Dementia (GIFTeD) trial: A non-invasive brain stimulation approach to modulate gamma activity, brain metabolism and cognitive performance in FTD patients**
Emiliano Santarnecchi¹
¹MGH - Harvard Medical School - Boston (United States)
- P202 Misfolding Of Biomarkers Stratifies Proteinopathies**
 Klaus Gerwert¹
¹Ruhr-University Bochum - Bochum (Germany)
- P203 Blood-Based small RNA Biomarkers and the ATN(V) Framework: Predicting Neurodegeneration and Vascular Profiles in the EPAD Cohort**
Bruno Steinkraus¹, Marco Heuvelman¹, Luigi Lorenzini², Julia Jehn¹, Tobias Sikosek¹, Rastislav Horos¹, Kaja Tikk¹, Jeffrey Cummings³, Jean Manson⁴, Craig Ritchie⁴
¹Hummingbird Diagnostics GmbH - Heidelberg (Germany), ²Amsterdam University Medical Center - Amsterdam (Netherlands), ³Department of Brain Health, Chambers-Grundy Center for Transformative Neuroscience, University of Nevada Las Vegas - Las Vegas (United States), ⁴Centre for Clinical Brain Sciences, The University of Edinburgh - Edinburgh (United Kingdom)
- P204 Evaluation of GLP-1 analogue, Liraglutide in the treatment of Alzheimer's disease**
Paul Edison¹
¹Imperial College London - London (United Kingdom)



CTAD 2023 VENUE

Boston Park Plaza

50, Park Plaza at Arlington
Boston, MA 02116, USA

The Boston Park Plaza is located at the heart of downtown Boston, just steps away from the Public Garden and Theater districts.

The conference hotel is sold out, for hotels nearby check out our accommodations page at www.ctad-alzheimer.com



CTAD 2023

Clinical Trials on Alzheimer's Disease

> LATE CALL FOR ABSTRACTS

opens: August 10

Deadline to submit September 7

Graphic designer: Mélanie Vaissette

Follow us on social media!



[@CTADConference](https://twitter.com/CTADConference)
[#CTAD23](https://twitter.com/CTADConference)



[CTAD Conference](https://www.facebook.com/CTADConference)



[CTAD Alzheimer](https://www.linkedin.com/company/CTAD-Alzheimer)

CTAD Congress > Email: ctad@ant-congres.com

www.ctad-alzheimer.com